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Abstract 
 
Nonsense mediated decay associated pioneer round of translation as source for 
peptides for presentation by MHC class I  
 
Nonsense mediated decay (NMD) plays a critical role in the mRNA quality control 
mechanism protecting cells from aberrant mRNAs containing premature termination 
codons (PTC). Recognition of these PTCs requires a pioneer round of translation prior to 
the bulk translation of mRNAs for cellular protein synthesis, therefore producing a pool 
of immediate early peptides. 
Effectiveness of the immune surveillance system is insured by the timely and complete 
MHC I mediated presentation of a pool of precisely cleaved peptides representing all 
cellular proteins. So far sources of antigenic peptides are known to include regular 
degraded proteins, defective ribosomal products (DRiPs) and cryptic peptides starting 
with a non-AUG start codon. Here the contribution of peptides originating from the 
pioneer translation to the pool of peptides presented by MHC I molecules is described. 
Depletion of the essential NMD factor hUpf1 as well as the pioneer translation initiation 
complex factors CBP80 and CBP20 reveal impaired MHC I antigen presentation. In 
sharp contrast, targeted interference with bulk translation without effecting pioneer 
translation permits antigen presentation. Taken together these findings put products of the 
pioneer round of translation into an important position as novel source for antigenic 
peptides and reveal a new relationship between NMD and immune surveillance. 
 
The most beautiful thing we can experience is the mysterious. It is the source of all true 
art and all science. He to whom this emotion is a stranger, who can no longer pause to 
wonder and stand rapt in awe, is as good as dead: his eyes are closed. 
 
Albert Einstein 
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 1. Introduction       
 
The first part of the introduction starts with a bird’s view of the immune system 
providing an overview of the recognition of pathogens and the different layers of defense 
against them. It will focus on the generation, processing and presentation of peptide 
sequences in adjunction to the Major Histocompatibility Complex. The second part will 
shine light on another surveillance mechanism of the cell, Nonsense Mediated Decay, 
insuring the integrity of the genetic information for protein translation. 
This study in its entirety will then demonstrate the interrelatedness and synergies of these 
two biological systems. 
 
 
1.1 The immune system  
 
Virtually all organisms have developed elaborate defense mechanisms to recognize and 
destroy pathogens. Simple unicellular organisms as well as complex eukaryotes were 
faced with the same central problem of immunology: the accurate, efficient and timely 
distinction between self and non-self structures. Within the evolution of vertebrates the 
immune recognition acquired additional levels of complexity, which can be divided into 
two major arms.  
The innate immune system as the evolutionary oldest part consists of several mechanisms 
including humoral defense, mucosal barriers and inflammation. It further encompasses 
germ line encoded pattern recognition receptors with the ability to detect structures 
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common to multiple groups of pathogens. In mammals the Toll-like receptors (TLR), 
originally discovered in Drosophila melanogaster (Anderson, Bokla et al. 1985; 
Anderson, Jurgens et al. 1985), take a central role in detecting microbial molecules. This 
group of transmembrane receptors bind to highly conserved features of pathogens 
including double stranded RNA from viruses and lipopolysaccharid (LPS), liptoteichacid 
(LTA), flagellin and unmethylated CpG DNA from bacteria (Medzhitov and Janeway 
1997). They represent the trigger of a signaling cascade activating multiple genes 
controlling the function of the complement system, the natural killer (NK) cells, cytokine 
secretion, apoptosis and phagocytosis. While the innate immune system can rapidly and 
successfully clear the organism from many infections, it is closely linked to the second 
line of defense – the adaptive immune system. Particularly NF-κB mediated activation of 
the interferon response serves as bridge between innate and adaptive defense (Barton and 
Medzhitov 2003). Interferon type I, consisting of INF α and β and the less characterized 
ε, κ, ω, δ and τ, is mainly expressed in virus infected cells. Interferon type II only 
comprises of one cytokine, INF γ. It takes a central role in activating the major 
histocompatibility class I and class II (MHC) pathway, the proteasome, apoptosis, natural 
killer cells and macrophages as well as inducing more than 200 other genes (Boehm, 
Klamp et al. 1997; Kloetzel 2004). 
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1.1.1 Adaptive immunity 
 
The adaptive immune system establishes immunological memory by recognizing 
previously encountered antigens and mounting a highly targeted immune reaction. 
It is composed of two arms, the humoral and cell mediated immune response. While both 
B-lymphocytes and T-lymphocytes have their origin in the hematopoietic stem cells of 
the bone marrow, their functions are highly specialized. The receptors expressed on the 
large and very diverse set of B-cells recognize pathogens in the extracellular milieu and 
induce defense through the secretion of antibodies. Pathogens that escape extracellular 
surveillance and that enter host cells become targets for cytotoxic CD8 T-lymphocyte 
detection and destruction. Host cells display antigens, short peptide sequences 
representing virtually all sources of protein originating from self or foreign structures 
inside the cell. Major histocompatibility complex class I (MHC I) molecules serve as 
crucial interaction partners ensuring the binding, conformation and integrity of the 
peptides for display to CD8 T-lymphocytes. In order for the antigen presentation pathway 
to create a complete and up to date “inventory of the cell” on its surface, multiple steps of 
a complex process have to be continuously and precisely orchestrated. Proteins and 
polypeptides are channeled through chaperones, cleaved by the proteasome and several 
proteases in the cytosol, transported by the transporter associated with antigen 
presentation (TAP), edited in the ER, loaded to MHC class I molecules and finally 
displayed on the cell surface for CD8 T-lymphocyte screening. These subsequent steps of 
the antigen presentation pathway will be discussed in detail. 
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1.1.2 The Major Histocompatibility Complex class I  
 
One of the most diverse proteins, MHC class I molecules are encoded in a large genomic 
region of the human chromosome 6 (chromosome 17 in mice) together with about 140 
other genes including MHC II, nonclassical MHCs and several other components of the 
immune system. Their discovery and initial description by George Davis Snell, Baruj 
Benacerraf and Jean Baptiste Dousset represents one of the hallmarks of modern 
immunology (Snell 1992). The biological significance was discovered by Zinkernagel 
and Doherty when observing that virus induced CD8 T-cells recognize virus infected 
cells in a MHC class I restricted way (Zinkernagel and Doherty 1974). MHC class I 
molecules consist of a membrane spanning 45 kDa α chain and a non covalently 
associated invariant 12 kDa β2m microglobulin chain. The alpha chain has three domains 
α1, α2 and α2 with the peptide binding groove positioned between α1 and α2. Each MHC 
class I molecule binds to a spectrum of different peptides consisting of 8 to 10 amino 
acids. The human leukocyte antigen (HLA) genes consist of HLA A, B and C as well as 
the non-polymorphic HLA E, HLA F, HLA G. Mouse MHC class I molecules have a 
distinct nomenclature with major antigens H-2K, D and L. A polymorphism with 
hundreds of alleles for each locus creates a remarkable diversity of expressed MHC class 
I molecules between individuals. Variations in HLA allele expression are a major 
determinant for susceptibility for many infections, tumor progression, auto immune 
diseases and transplantation tolerance (Nolan, Gaudieri et al. 2006). While MHC class I 
molecules are expressed in almost all nucleated cells in order to insure complete 
surveillance and protection from infections and potentially harmful mutations their 
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expression level varies considerably. Lymphocytes show relatively high expression levels 
of around 5 x 105 MHC class I molecules per cell in comparison to fibroblast, liver and 
muscle cells with low expression. Some neuron and sperm cells have almost undetectable 
levels of MHC class I surface expression.  
 
 
1.1.3 The MHC class I - peptide interaction: a perfect match 
 
Allelic variation creates hundreds of different MHC class I molecules but it is no match 
for the level of diversity added by the peptides. The interface between the MHC class I 
molecule and the peptide has to achieve an extraordinary task therein: binding to a huge 
array of different peptides from virtually all self and foreign protein sources while 
retaining the ligand on the cell surface and ensuring access for the T-cell receptor (TCR) 
for recognition. A first insight into the MHC class I peptide interface was gained when 
crystallographic structures of the MHC became available. The α1 and α2 chains each 
contribute four strands of an antiparallel β-sheet and a long interrupted helix to built an 
approximately 30 Å long and 12 Å wide peptide binding groove (Madden 1995; Rudolph, 
Stanfield et al. 2006). Particularly the residues pointing inside this groove comprise high 
variability enabling to interact with a multitude of ligands. In contrast to the MHC class II 
binding grove both ends are closed by a set of highly conserved residues limiting the 
maximum length of ligand chains. The MHC class I molecules are only stable with a 
bound peptide. Eluting peptides from MHC class I molecules and subsequent sequencing 
helped to define conserved and flexible residues of the peptide ligands and to create 
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valuable bioinformatics tools for antigen sequence analysis (Falk, Rotzschke et al. 1991). 
One or two positions p2, p3 and the p9 C-terminus are usually highly conserved anchor 
residues ensuring a stable interaction with the MHC class I molecule. This leaves high 
flexibility for the remaining six or seven residues creating diversity in the magnitude of 
108 different peptides (Shastri, Schwab et al. 2002).While the vast majority of peptides 
are between 8 and 10 amino acids in length some exceptions due to bulging and 
extension over the peptide groove have been described (Fremont, Matsumura et al. 1992; 
Collins, Garboczi et al. 1994; Speir, Stevens et al. 2001). Finally it should be noted that 
MHC class I molecules are not just passive recipients of their ligands but rather actively 
involved in their generation. In what is called the “Rammensee-Paradox” two contrary 
ideas propose either the rapid generation and protection of peptides exclusively in the 
cytosol or the binding and subsequent trimming of peptides with MHC class I molecules 
acting as templates in the ER (Shastri, Schwab et al. 2002). Recent evidence points the 
way to common ground of these hypotheses with MHC class I molecules binding to 
suitable peptides and providing protection from further degradation together with 
additional trimming to finalize the peptide in the ER (Kanaseki, Blanchard et al. 2006). 
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1.1.4 Origins of antigenic peptides presented by MHC class I molecules 
 
1.1.4a Defective Ribosomal Products (DRiPs) 
 
The efficiency of the MHC class I immune surveillance depends on the complete, 
continuous and rapid presentation of virtually all self and foreign sources of peptides. For 
a long time antigenic peptides have been thought to predominantly originate in 
conventional cellular proteins being degraded according to their normal half live (Moore, 
Carbone et al. 1988). This concept was initially supported by findings correlating the 
protein stability and degradation to the rate of cell surface presentation for at least some 
particular proteins (Grant, Michalek et al. 1995; Sijts and Pamer 1997). Cellular proteins 
have a half -life ranging from minutes to several days with an estimated average life span 
of 10 hours before being degraded and becoming potential sources of antigen 
presentation. Within the last 10 years it became more and more clear that antigen 
presentation is often closely linked to new synthesis of polypeptides (Yewdell and 
Nicchitta 2006) . Evidence from several studies suggests that 30% or more of newly 
synthesized proteins are directly funneled into destruction through the interplay of the 
proteasome and several peptidases. Several hypotheses have been postulated to explain 
the fast degradation of these polypeptides with defective ribosomal products (DRiP’s) 
being the most prominent concept. This idea suggests that many newly generated 
polypeptide chains cannot fold to their correct three dimensional confirmation within a 
certain time frame. The reason for the inability of these peptide chains to achieve their 
correct tertiary structure has been target of much speculation. Alternative reading frames 
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or problems in the mRNA generation, protein biosynthesis, translation termination, sub-
cellular targeting or assembly with subunits and folding factors have been proposed.  
Further it has been observed that the generation of antigenic peptides is independent of 
the stability of endogenously synthesized peptides (Goth, Nguyen et al. 1996). Therefore 
not the normal protein turnover but a certain subset it is relevant for antigen presentation. 
Additionally a set of potent chemical inhibitors of various stages of protein biosynthesis 
played a crucial role in elucidating the direct relationship between translation and 
antigenic peptide generation. Several previous studies as well as experimental data herein 
narrowed down the time required for translation of many antigenic peptides to less than 
10 minutes (Schubert, Anton et al. 2000). Particularly in the case of viral evasion of a 
cell, fast availability of antigens from immediate early gene products as well as of often 
long lived coat proteins becomes crucial for efficient host defense. Taken together 
monitoring protein synthesis as opposed to cellular protein turn over simply makes 
immunological sense. 
 
 
1.1.4b Rapidly degraded Products (RDPs) 
 
In contrast to DRiPs the term rapidly degraded products (RDPs) refers to the majority of 
otherwise normal, physiologically relevant nascent polypeptide chains in healthy cells 
that are degraded prior to reaching their destined functional conformation. (Qian, 
Princiotta et al. 2006) Cells maintain a fine balance between chaperone assisted folding 
and degradation through the ubiquitin or other pathways (Hershko, Ciechanover et al. 
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1979; Wilkinson 2005) It was shown that a large subset of nascent polypeptide chains, 
probably up to 70% are targeted for immediate degradation. 
 
 
1.1.4c Cryptic Translation 
 
For long translation was manifested as ribosomal recognition of an AUG start codon and 
generation of a continuous polypeptide chain subsided by folding to a predetermined 
protein conformation. Recent findings draw a different picture demonstrating several 
sources of unconventional or therefore cryptic translation products (Shastri, Schwab et al. 
2002; Ho and Green 2006) Alternative mRNA splicing as well as frame shift events 
during transcription account for the generation of multiple antigenic peptides that 
efficiently initiate cytotoxic T-cell responses. Further examples include the recognition of 
alternative reading frames using downstream AUG codons for initiation as well as 
translation of conventionally untranslated regions in the 5’UTR and 3’UTR or intron 
sequences (Uenaka, Ono et al. 1994; Guilloux, Lucas et al. 1996). The now common 
practice of cell transfection of mini-genes encoding only short peptide sequences further 
illustrates the obsolescence of full length proteins for successful T-cell recognition. In 
stark contrast to a long prevailing dogma translation initiation can occur at codons other 
than AUG (Peabody 1989). At least six different initiation codons have been identified 
that result in peptide generation and constitutive display by MHC class I molecules. 
Especially for the case of CUG mediated initiation, consistent levels of CD8 T-cell 
activating antigens are observed in vitro using mini-genes as well as in a transgenic 
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mouse model (Malarkannan, Horng et al. 1999; Schwab, Li et al. 2003; Schwab, Shugart 
et al. 2004). Surprisingly initiation with CUG encodes a leucine rather than a “wobble” 
methionine. Current studies utilize primer extension inhibition assays, so called “toe-
printing”, as means to monitor the precise binding region of the initiating ribosome. 
Several compounds have been identified that differentially impact CUG or AUG 
mediated initiation of translation (Green, Ow et al.; Kozak and Shatkin 1978). Especially 
with the discovery of internal ribosomal entry sites (IRES) it became clear, that 
alternative machineries of translation not only appear in mammalian cells but serve 
distinct functions far beyond their original viral role (Pfingsten and Kieft 2008). Different 
regulatory and refining mechanisms of translational control will be discussed later. So far 
these findings pave the road for future hypotheses about an alternative CUG based 
initiation mechanism that can generate antigenic peptides. The function of CUG start 
codons in the biosynthesis of full length proteins still remains to be elucidated. 
 
 
1.1.4d Antigens generated through peptide splicing 
 
Another pool of unanticipated antigens involving peptide splicing was discovered. 
Usually MHC class I presented peptides are expected to consist of a continuous sequence 
of 8 to 10 amino acids. Vigneron et al. demonstrated the antigenicity of two non-
continuous and rejoined peptide fragments of melanocytic glycoprotein (gp100) in 
melanoma cells (Vigneron, Stroobant et al. 2004). An initial 13mer precursor peptide 
required proteasomal processing resulting in the excision of four amino acids and 
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subsequent trans-peptidation involving an acyl-enzyme intermediate in order to be 
recognized by human CD 8 T lymphocytes. Similarly Hanada et al. have shown the 
immune recognition of a fibroblast growth factor-5 (FGF-5) derived spliced nonamer 
peptid (Hanada, Yewdell et al. 2004). The diversity of unconventional peptide sources 
recently reached a highlight with the unanticipated example of a 10 residue peptide 
consisting of a tetra- and hexamer being rejoined in reverse order (Warren, Vigneron et 
al. 2006). 
 
 
1.1.4e Cross-presentation of peptides 
 
Cross-presentation denotes the ability of antigen presenting cells (APC’s) to receive, 
process and present exogenous peptides via MHC class I molecules on their cell surface 
to trigger CD 8 T-cell activation. Cross-presentation considerably deviates from some 
characteristics of other antigenic sources described above as it is more prone to utilize 
full length protein. The ability to present exogenous peptide is mainly limited to dendritic 
cells (DC) with marked differences between distinct subsets of cells (Mellman and 
Steinman 2001; Guermonprez and Amigorena 2005). This process is particularly 
important for the immune surveillance of cells that do not actively undergo antigen 
presentation themselves. It enables dendritic cells to present viral or tumor antigens even 
in the case that they are not directly effected therefore closing an otherwise detrimental 
gap in the immune defense. While the phenomenon of cross-presentation is already 
known since 1976, several details of the pathway remain in the dark (Bevan 1976; Bevan 
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1976). Exogenous material is largely acquired by endocytosis of whole or partial cells 
leaving potential antigens in the phagosome. This opens the question of how peptides 
reach the cytosol and proteasome for further processing. “Leaky” passing through the 
phagosomal membrane as well as a specific transport mechanism involving Sec61 are 
current possibilities under investigation (Ackerman, Giodini et al. 2006). Alternatively 
fusion of phagosomes with the ER compartment and direct processing and loading of 
antigenic peptides to MHC class I molecules within the lumen of the phagosome has been 
proposed (Rock and Shen 2005). A remarkable extension of established cross-
presentation pathways imposed the demonstration of active transfer of peptides between 
the cytosol of adherent cells through gap-junctions into antigen presenting cells 
(Neijssen, Pang et al. 2007). Additionally various approaches of cancer immunization 
using antigens, completely folded tumor proteins as well as whole cells prove the 
importance of cross-presentation for in vivo immune functions (Osanto 1997). 
 
 
1.1.4f Pioneer round of translation peptides 
 
Pioneer round of translation peptides are by definition the polypeptides generated within 
the first round of translation of each newly transcribed and spliced mRNA.  They were 
discovered in the context of an mRNA surveillance mechanism called Nonsense 
mediated decay (NMD)  and might combine several of  the features of peptide sources 
described so far. At this point the subsequent steps of the generation and processing of 
antigens  to their final presentation on the cell surface will be followed. The important 
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and novel role of pioneer peptides will be introduced within the context of NMD and 
described in detail in section 1.2. 
 
 
1.1.5 Creating antigenic precursors through proteasomal degradation  
 
Despite the very different life time of structural proteins or unfolded polypeptide chains 
they eventually reach their fate of proteolysis through the proteasome and cytosolic 
proteases. The central function of the proteasome is the degradation of nuclear, cytosolic 
and transmembrane proteins that have reached their life span. While this process is 
crucial for the elimination of regulatory or infunctional proteins it also generates 
precursors of antigenic peptides of various length and stability for MHC class I mediated 
presentation. Crucial findings about the importance and direct involvement of the 
proteasome for antigen presentation came from studies with small molecule inhibitors. 
After the initial finding of reduced antigen presentation of a chicken ovalbumin derived 
peptide by MHC class I molecules various inhibitors like LLnL, MG115, MG132, 
lactacystin and to a lesser extent LLM became an important tool to study antigen 
presentation (Rock, Gramm et al. 1994; Anton, Bennink et al. 2001). The 26S proteasome 
consists of a barrel-shaped 20S catalytic core domain harboring all catalytically active 
residues and two 19S subunits that define substrate specificity. The proteasome 
recognizes polyubiquitin-labels and other degrons of proteins earmarked for destruction 
and degrades them in an ATP dependent process (Varshavsky 1997). Interestingly the 
two proteasomal subunits LMP2 and LMP7 are encoded in a INF γ controlled gene 
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region in direct proximity to the TAP-genes indicating their importance for the immune 
response.  Upon INF γ induction these chains replace the constitutively expressed 20S 
proteasome subunits. This complex with altered proteolytic functions is called the 
immunoproteasome. The proteasomal activator PA28 has been described as an 
interaction partner, which induces small conformational changes of the 20S proteasome. 
These alterations potentially induce subtle changes in the orientation of some of the 
active residues of the 20S proteasome leading to the generation of slightly longer 
peptides. Accordingly it has been demonstrated that the expression level of PA28 alters 
the pool of recognized antigens on the cell surface (Sun, Sijts et al. 2002). With the 
discovery of the proteasome maturation protein (POMP) another factor entered the 
complex stage of proteasomal regulation. POMP serves as a chaperone tightly regulating 
the assembly and deterioration of the immunoribosome. In response to viral induced 
cytokine release the immunoribosome is rapidly up regulated while cells smoothly return 
to constitutive proteasome expression when an immune response becomes obsolete 
(Heink, Ludwig et al. 2005). Constitutive expression of the immunoribosome in immune 
privileged brain and ocular tissue as well as indications of altered CD8 T cells gave rise 
to the idea of some involvement in alternative immunological processes beyond antigen 
presentation (Chen, Norbury et al. 2001; Singh, Awasthi et al. 2002). Other proteases like 
leucine aminopeptidase and tripeptidyl peptidase (TPP) seem to be involved in cytosolic 
processing even thought their effect on the surface antigen repertoire remains to be 
demonstrated conclusively (Stoltze, Schirle et al. 2000; Reits, Neijssen et al. 2004).  
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1.1.6 Chaperone function and antigen processing in the cytosol 
 
The folding, assembly and eventually the degeneration of proteins is largely dependent 
on the interplay of chaperones, proteases and the proteasome. A role of chaperones in 
protecting them from their ultimate fate of degradation into single amino acids, in 
regulating subcellular peptide concentration and in guiding them to MHC class I 
molecules has been suspected for long (Li and Srivastava 1994). Among others the 
chaperones GRP94, HSP90, GRP78 and HSP70 have been associated with altered 
antigen presentation and CD8 T-cell recognition while their precise interaction 
mechanism with the proteolytic peptide intermediates remained unresolved (Gullo and 
Teoh 2004). A detailed analysis of HSP90 revealed its interaction with C-terminally 
extended peptide precursors taking advantage of the well characterized SIINFEKL 
system in conjunction with high performance liquid chromatography (HPLC) 
fractionation. Differential RNA interference mediated depletion demonstrated the crucial 
function of HSP90α as well as the co-chaperonin CHIP in protecting and channeling C-
terminally extended precursors for MHC class I loading (Kunisawa and Shastri 2006).  
In a previous study the selective role of group II chaperonine TRiC for the expression of 
peptide-loaded MHC class I molecules on the cell surface became evident (Kunisawa and 
Shastri 2003). Accordingly also chemical inhibition of HSP90 with radiciol 
geldanamycin , 17-DMAG and 17-AAG showed the generation of “empty” MHC class I 
molecules and reduced levels of T-cell activation. So far a predominantly post-
proteasomal role for the interaction of HSP90 antigenic precursors is anticipated by the 
authors (Callahan, Garg et al. 2008). Very recently HSP90 has been also reported to 
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directly facilitate the assembly and function of the 26S proteasome therefore 
subsequently accounting for alterations in the surface presentation of peptides bound to 
MHC class I molecules (Yamano, Mizukami et al. 2008). Additional observations of 
HSP90 participation in DC mediated cross-presentation are a reminder that our 
understanding of the complete picture of chaperone function in antigen presentation still 
requires further elucidation (Giodini and Cresswell 2008). 
 
 
1.1.7 From cytosol to ER: peptide transport via TAP 
 
The transporter associated with antigen processing (TAP) was almost simultaneously 
discovered by four laboratories in 1990. Initially two genes were found in direct 
proximity to the MHC locus with high sequence homology to ABC (ATP Binding 
Cassette) transporters. They encode a dimeric transmembrane complex named TAP1 and 
TAP2 that turned out to be responsible for the ER translocation of the waste majority of 
antigenic peptide precursors (Deverson, Gow et al. 1990; Monaco, Cho et al. 1990; Spies, 
Bresnahan et al. 1990; Trowsdale, Hanson et al. 1990). The TAP mutant human cell line 
LBL 721.134 (TAP1 mutant) (Cerundolo, Alexander et al. 1990) as well as the murine 
cell line RMA-S (TAP2 mutant) (Powis, Townsend et al. 1991) were crucial in 
establishing a functional link between wildtype TAP1 and TAP2 expression and MHC 
class I mediated CD8 T-cell stimulation. In both cell lines MHC class I peptide 
presentation could be reestablished by DNA transfection of TAP1 or 2 gene encoding 
DNA sequences. Severely reduced MHC class I surface expression as well as complete 
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absence of CD4 and CD8 T-cells was also observed in a TAP1 deficient mouse (Van 
Kaer, Ashton-Rickardt et al. 1992). Peptide translocation assays using N-glycosylated or 
respectively radiolabeled peptides in Streptolysin O permeabilized cells added the final 
evidence for the ATP-dependent ER translocation of antigenic peptides through TAP 
(Androlewicz, Anderson et al. 1993; Neefjes, Momburg et al. 1993). Androlewicz et al. 
further determined the preferred length of peptides transported by TAP as between 8 to 
12 amino acids. Peptide chains in the length of 13-30 amino acids are transported to a 
much lesser extent while longer peptides are inevitably cleaved prior to transport. A clear 
correlation between the sequence requirements for TAP transport and the binding 
preferences of their respective MHC class I became evident. Human peptides allow a 
larger variety of peptide sequences both for TAP transport and MHC class I binding 
while mouse peptides are on the other side of the spectrum with more restrictive sequence 
specificity. The C-terminal flanking residues are a major determinant for TAP transport 
with basic and hydrophobic amino acids being more efficiently translocated in mouse, 
human and rat cells (Androlewicz and Cresswell 1996). While preferences for TAP 
transport generally reflect the requirements for MHC class I binding there are some 
marked exceptions. Four immunodominant viral peptides were found to be very 
inefficiently transported by TAP. A proline in position 3 was identified as a consensus 
amino acid preventing efficient TAP transport (Neisig, Roelse et al. 1995). A seminal 
study described the importance of new translation for TAP mediated transport of peptides  
emphasizing not only sequence features but also the origin of a peptide for efficient 
transport and presentation. In this case the authors used fluorescence recovery after photo 
bleaching (FRAP) with a TAP1 green fluorescence (GFP) fusion protein in order to 
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determine TAP1 mobility within the ER membrane as a measure for active peptide 
translocation (Reits, Vos et al. 2000). Different alleles encoding the TAP1 and 2 complex 
helped to gain further insight into the mechanism of TAP transport. The alternative rat 
allele RF1.Aa enabled to directly analyze the changes in MHC class I peptide surface 
presentation due to selectivity of the TAP transport (Powis, Young et al. 1996; Knittler, 
Gulow et al. 1998). Over the time of evolution viruses have developed evasion strategies 
against almost all major components of the immune system. TAP remains no exception.  
The Herpes simplex virus (HSV) expresses immediate early protein ICP47 which binds 
to TAP therefore preventing any further viral peptides from translocation and antigen 
presentation (Fruh, Ahn et al. 1995; Hill, Jugovic et al. 1995). Similarly proteins like 
human cytomegalovirus derived US6, the bovine herpesvirus type 1 encoded UL49.5 and 
the BNFL2a protein of Eppstein Barr virus bind to TAP and introduce subtle 
conformational changes to arrest transport (Hislop, Ressing et al. 2007; Oosten, Koppers-
Lalic et al. 2007). Finally there are some TAP independent pathways that lead to 
productive MHC class I loading and surface presentation of peptides. In the case of the 
completely TAP deficient human cell line T2 721.174 no surface expression of MHC 
class I HLA B and HLA C, but about 20-50 % of normal surface presentation of MHC 
class I HLA A2 can be detected. Here signal sequence derived peptides translocated into 
the ER by the signal recognition pore SRP account the for the supply of antigenic 
peptides (Wei and Cresswell 1992). 
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1.1.8 The ER based Peptide Loading Complex 
 
MHC class I molecules mostly receive their peptides when associated to TAP as well as 
to the peptide loading complex (PLC). This multi protein mechanism consisting of 
calnexin, calreticulin, tapasin, ERp57 and several further factors coordinates peptide 
binding, quality control and editing in a precisely orchestrated process (Peaper and 
Cresswell 2008). 
As a prerequisite of peptide binding calnexin facilitates correct assembly and folding of 
the microglobulin β2m jointly with the heavy chain (HC). This 90 kDa transmembrane 
protein includes a globular domain mediating glycan binding as well as a P-domain 
important for ERp57 interaction. The ER resident chaperone calnexin prevents protein 
aggregation and helps to target missfolded protein for degradation (Molinari, Eriksson et 
al. 2004). Together with the homologous lectin calreticulin they both act in a calnexin-
calreticulin cycle facilitating the folding of glycoproteins while exposing them to 
additional folding factors such as the below mentioned ERp57 (Hammond and Helenius 
1993). Taken together MHC class I peptide assembly can be envisioned as a distinct 
process of protein folding with the involvement of multiple chaperones. 
 
Within the PLC tapasin serves as an initial factor insuring the stability of the complex as 
well as the optimal loading of the MHC class I molecule. Tapasin is a 48 kDa 
transmembrane glycoprotein with an ER signal sequence encoded in the MHC locus of 
chromosome 6. It mediates the contact between TAP and the MHC class I molecule after 
assembly of the heavy chain and the microglobulin β2m (Grandea, Androlewicz et al. 
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1995; Ortmann, Copeman et al. 1997). Detailed analysis on the stochimetric interaction 
demonstrated a 4:4:1 ratio of MHC class I, tapasin and TAP molecules (Bangia and 
Cresswell 2005).  A recent study using blue native-PAGE introduced some controversy 
postulated two distinct oligomers of 350 and 450 kDa with the larger consisting of 2 
tapasin molecules and each one MHC class I and calreticulin molecule (Rufer, Leonhardt 
et al. 2007). While the precise mechanism of tapasin remains unknown at least two 
distinct functions have been described. First tapasin increases the peptide-binding affinity 
of MHC class I peptide complexes as shown in a non-peptide-specific approach 
(Williams, Peh et al. 2002). Second it exerts a quality control function in the ER 
preventing the export of empty or low affinity MHC class I peptide complexes to the 
golgi network (Barnden, Purcell et al. 2000). Several additional functions have been 
suggested linking tapasin to TAP stability and transport efficiency, dissociation of 
peptides from MHC class I molecules and direct interaction with ERp57 among others. 
While tapasin is essential for the vast majority of peptides being loaded to MHC class I 
molecules there are reports of several cases with very low tapasin dependency (Peh, 
Burrows et al. 1998; Goodall, Ellis et al. 2006). Most striking is the case of HLA-B 4405 
and HLA-B 4402 where a single amino acid exchange accounts for a large difference in 
tapasin requirement for folding, maturation and antigen presentation (Park, Lee et al. 
2003). 
Only recently the covalent association of tapasin with the thiol oxidoreductase ERp57 
was discovered (Peaper, Wearsch et al. 2005). ERp57 belongs to the family of protein 
disulfide isomerases (PDI) functioning in oxidative glycoprotein folding. Beyond its 
involvement in the PLC it is widely distributed in the cell including the cell surface, 
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cytosol and nucleus (Turano, Coppari et al. 2002). A mouse model with B-cell specific 
ERp57 depletion leading to a strong reduction of MHC class I Kb and Db surface 
presentation provides evidence for its important role in antigen presentation (Garbi, 
Tanaka et al. 2006). Further ERp57 increases the interaction time between tapasin, MHC 
class I potentially by inducing a conformational change within tapasin. Taken together 
ERp57 seems to be a central stabilizer of the PLC due to its covalent bond with tapasin 
and weak interactions with calreticulin.  
 
 
1.1.9 The final cut: peptide editing in the ER 
 
In addition to the mere folding and binding events described in the previous paragraph 
peptides in the ER undergo a precise editing and trimming process to obtain the final 
peptides for MHC class I mediated antigen presentation. Proteolytic intermediates that 
reach the ER typically include N-terminal extensions imposing the requirement for 
further processing within the ER (Paz, Brouwenstijn et al. 1999; Rock, York et al. 2004; 
Kanaseki, Blanchard et al. 2006). The C-termini are often already cleaved at their final 
position within the cytosol. These crucial observations were initially made when 
analyzing the transport and processing of peptides including prolin residues. As 
mentioned above, an aminoterminal proline at the position p1, p2 and p3 (called X-P, 
X=any amino acid, P= prolin) makes notoriously bad substrates for TAP binding and 
transport (Neisig, Roelse et al. 1995; van Endert, Riganelli et al. 1995). But despite their 
poor translocation properties particularly a prolin at anchor position p2 represents a very 
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frequent antigen sequence presented by MHC class I molecules (Rammensee, Bachmann 
et al. 1999). This conundrum was resolved with the discovery of the ER resident amino 
peptidase associated with antigen processing (ERAAP). N-terminally extended peptides 
(Xn-P, n≥2) with the proline “hidden” in the center of the peptide intermediate are 
efficiently transported by TAP and are precisely cleaved only upon arrival in the ER. 
ERAAP was initially purified from mouse microsomes. The interferon γ inducible protein 
in localized in the ER with a similar distribution as MHC class I molecules. Reduction of 
the aminopeptidase activity using the inhibitor leucinethiol as well as RNAi mediated 
depletion revealed the functional role of ERAAP in cleaving peptide N-termini to 
generate the final antigens (Serwold, Gonzalez et al. 2002). The analysis of mice 
deficient of ERAAP demonstrated changes of MHC class I surface expression (Hammer, 
Gonzalez et al. 2006; York, Brehm et al. 2006). These were not only manifested in the 
overall number of MHC class I molecules on the cell surface but rather in a difference of 
the diversity of antigens presented on the surface.  While the surface expression of MHC 
class I molecules H-2Kb, H2-Kd, H2-Db and H2-Dd only decreased about 20%, H-2Ld 
was reduced 70% in ERAAP deficient mice. Interestingly only H-2 Ld molecules include 
X-P peptides with a prolin at position 2 in their repertoire. MHC class I peptide 
complexes in ERAAP deficient cells showed a reduced binding quality with a 10-20% 
higher dissociation rate. Most strikingly at least two peptides recognized by the T-cell 
hybridoma 30NXZ (H13-H-2Db) and 1AZ (H47-H-2Db) showed a significant increase in 
HPLC purified extracts of ERAAP -/- splenocytes (Hammer, Gonzalez et al. 2006). 
Detailed analysis of the antigen repertoire revealed not only a large group of peptides 
dependent on ERAAP expression but also a group of peptides that are presented on the 
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surface despite their incomplete trimming by ERAAP. These peptides uniquely expressed 
in ERAAP deficient cells induce strong immunogenicity in their wildtype counterparts 
(Hammer, Gonzalez et al. 2007). Additionally there is evidence that ERAAP acts in a 
synergetic cooperation jointly with the MHC molecule to generate the final MHC class I 
peptide complex (Paz, Brouwenstijn et al. 1999; Kanaseki, Blanchard et al. 2006). Taken 
together ERAAP is not only shaping the antigen repertoire but has been identified as the 
central ER resident aminopeptidase required for antigen trimming in mice. In human cells 
a homologeous ERAAP (also termed ERAP1) interacts with another ER resident 
aminopeptdase L-RAP (also called ERAP 2) in order to generate the final antigens (Saric, 
Chang et al. 2002; Tanioka, Hattori et al. 2003; Saveanu, Carroll et al. 2005).   
 
 
1.1.10 MHC class I recognition and CD8 T-cell response 
 
All T-cells originate as double negative hematopoietic stem cells of the bone marrow. As 
they progress in their development they migrate into the thymus and rearrange their TCR 
genes. Those with productive CD8 rearrangement subsequently pass through positive and 
negative selection leading to a population of lymphocytes that confer both MHC class I 
self restriction and self tolerance. This process leaves a diverse pool of mature 
immunocompetent CD8 T-cells that have a high reactivity to potentially foreign antigens.  
These naïve CD8 T-cells remain as resting cells in a G0 stage of the cell cycle while 
continuously circulating between the blood and lymph system. Upon TCR recognition of 
an appropriate antigen presented by a MHC class I molecule, the T-cell mounts a primary 
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immune response and enters into cell cycle progression and upregulation of IL-2. While 
effector T-cells carry out multiple functions from cytokine secretion to cytotoxic killing 
another subset serves as memory T cells ensuring a secondary response if ever 
encountering the same antigen again.   
Alterations within the pool of presented antigens often manifest themself in a reduced 
number of CD8 T-cells. Depletion or mutations of many of the components of the MHC 
class I antigen presentation pathway discussed in the paragraphs above lead to a severely 
deficient CD8 T-cell repertoire. Lack of TAP, tapasin or β2m leads to an almost total 
depletion of CD8 cells. Absence of ERAAP, LMP-7, LMP-2, LMP-10 and PA28β 
predominantly induce a reduction in the diversity while maintaining similar total numbers 
of CD8 T-cells. 
 
 
1.1.11 Antigen Presentation and Immunodominance  –  not just a numbers game 
 
Antigen presentation and CD8 T-cell recognition serve the ultimate goal to filter out 
those very few foreign antigens derived from viruses, bacteria or mutated proteins out of 
an ocean of peptides originating from host cell proteins. The complexity of this task and 
the sheer numbers of molecules involved are astonishing and deserve some further 
consideration.  
Immunodominance is defined as the ability of a particular antigen to be generated, 
presented and recognized by CD8 T-cells to finally mount a strong, specific immune 
response. A step down the hierarchy are subdominant antigens which trigger weak to 
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barely detectable immune responses. Of all the peptides only an estimated 1% bind to 
MHC class I molecules with an minimum MHC class I affinity of about   Kd>500 nM 
required for surface presentation (Yewdell 2006). Generation through translation, 
proteolytic liberation, efficient TAP transport, MHC class I allel expression and 
respective binding and finally the numbers of afferent APCs and their complementary T-
cells all contribute to immunodominance. Moutaftsi et al. examined the 
immunodominance hierarchy for the example of the vaccinia virus WR strain (VACV-
WR) (Moutaftsi, Peters et al. 2006). The following numbers represent a rough picture: 
From a theoretical pool of 175,000 potential poxvirus 8, 9 or 10mer antigens about 
35,000 are proteolytically liberated, 30,000 are transported by TAP, 150 bound by MHC 
class I, 75 recognized by a TCR and finally 50 are actual antigens leading to a immune 
response. Many of the immunodominant viral antigens represent early gene products 
underlining the importance of a fast generation and presentation of MHC class I peptides 
(Yewdell 2006). The absolute number of a MHC class I peptide complex required to 
trigger a T-cell recognition is believed to be in the magnitude of about 10 molecules per 
cell surface. Understanding immunodominace mechanisms is particular important for 
vaccine generation, cancer treatment as well as gaining insight into autoimmunity. 
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1.2 Nonsense Mediated Decay  
 
1.2.1 Nonsense Mediated Decay and Antigen Presentation 
 
Previous sections stressed the varied origins of peptides that are utilized for antigen 
presentation. Within the vivid field of Nonsense Mediated Decay (NMD) a completely 
unanticipated source of translational products was brought to the light. This mRNA 
control mechanism screens for premature termination codons (PTCs) 55 or more 
nucleotides upstream of an exon exon junction. Since stop codons are only defined within 
an open reading frame by screening through a ribosome, this imposed the requirement of 
a pioneer round of translation of each mRNA prior to the onset of bulk translation. The 
very first round of translation is known to require a set of specific factors associated with 
the exon junction complex (EJC), which is removed by the initial passage of the first 
ribosome. These pioneer round of translation peptides represent the first translation 
products of an mRNA transcript prior to the production of functional proteins on a large 
scale. This makes them an ideal source of peptides for MHC class I mediated 
presentation without any “additional cost” to the cell demonstrating the synergy of two 
major surveillance mechanisms     -    “at the cross roads of NMD and MHC I”.  
 
1.2.2 The Discovery of Nonsense Mediated Decay 
 
While the cellular machinery has multiple quality control mechanisms in place to insure 
the extraordinary high fidelity of the protein production machinery, mistakes do occur. 
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Especially truncated proteins, which are initially translated but lack a functional residue 
or domain are particularly harmful as they may act as dominant negative factors 
counteracting their original purpose in the cell. Examples for human diseases associated 
to partially translated proteins are abundant and well documented ranging from many 
forms of cystic fibrosis to β-thalassemia. An estimated 30% of all hereditary diseases are 
due to a frame shift or nonsense mutation resulting in a premature termination codon 
(Frischmeyer and Dietz 1999).  In many cases a direct relationship between the severity 
of the phenotype and the position of the PTC could be identified (Hall and Thein 1994). 
But the earliest reports date back to as far as the 70s when the destabilizing effect of 
premature termination codons on mRNA transcripts was observed in yeast (Losson and 
Lacroute 1979).  Soon the importance of intron positioning in relationship to the 
premature termination codon and splicing events was understood as well (Senapathy 
1986). In the field of immunology VDJ rearrangement of the T-cell receptor and the 
immunoglobulins (Ig) come to mind. This particularly prominent mechanism of 
alternative splicing is prone to creating two thirds of unproductive rearrangements do to 
frame shifts and subsequent nonsense mutations. Cesar Milstein and colleagues observed 
the down regulation of mRNA transcripts that encorporated nonsense codons when 
studying the hypermutation mechanism for the antibody response (Lozano, Maertzdorf et 
al. 1994). Similar observations were made by the Koehler laboratory. The group reported 
that the extent of reduction in mutated IgM-mRNA levels directly depends on the 
position of the nonsense codon within the gene (Baumann, Potash et al. 1985). A quality 
control mechanism down regulating the expression of unproductive TCR mRNA 
transcripts was found thereafter (Li and Wilkinson 1998; Gudikote and Wilkinson 2002). 
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By today several seminal discoveries have been made to understand the mechanism and 
several sub-pathways to deal with premature termination codons in organisms as different 
as Saccharomyces cervisiae, Arabidopsis thalia, Caenorhabdits elegance, Drosophila 
melanogaster, Mus musculus and Homo sapiens (Behm-Ansmant, Kashima et al. 2007). 
Early embryonic lethality and extinction of all hematopoethic stem cells in mouse models 
deficient of central factors of nonsense mediated decay leave no doubt of the essential 
importance of this process for life (Medghalchi, Frischmeyer et al. 2001; Weischenfeldt, 
Damgaard et al. 2008). 
 
 
1.2.3 Nonsense Mediated Decay: The components 
 
1.2.3a UPF proteins, central factors of NMD 
 
Within the last decade the picture of post transcriptional quality control and mRNA 
regulation has become much more complex. The lifetime of mRNAs is largely 
determined by their interaction with a plethora of host factors (Moore 2005). The central 
determinants of the NMD machinery are the up-frameshift proteins Upf1, Upf2 and the 
two alternative forms Upf3a and Upf3b (also termed Upf3 and Upf3X). Originally 
discovered in yeast, homologue proteins were so far described in all other eukaryotic 
organisms examined (Leeds, Wood et al. 1992; Cui, Hagan et al. 1995; Lee and 
Culbertson 1995). In mammalian cells Upf proteins are part of a large multi protein exon 
junction complex (EJC) consisting of at least 12 factors including Y14, eIF4AIII, 
 29 
MAGOH and MLN51 (Le Hir, Izaurralde et al. 2000; Le Hir, Moore et al. 2000). Upf1, 
The by far best described component is Upf1, a 130 kDa group 1 ATP-dependent 
helicase with binding domains for Upf2, Upf3 and mRNA.  
The localization of Upf1 as a shuttle protein both in the cytosol as well as in the nucleus 
reflects its separable functions both as final trigger for the mRNA decay cascade as well 
as in facilitating the early mRNA biogenesis (Wang, Czaplinski et al. 2001; Mendell, ap 
Rhys et al. 2002; Isken, Kim et al. 2008). The imminent role of Upf1 becomes evident in 
the embryonic lethality of Upf1 knock out mice and the failure to generate vital Upf1 
negative embryonic fibroblast cell lines (Medghalchi, Frischmeyer et al. 2001; 
Weischenfeldt, Damgaard et al. 2008). The function of Upf1 is vigilantly regulated in a 
cycle of phosphorylation and dephosphorylation requiring at least four different factors. 
While the suppressor with morphogenetic effect on genitalia-1 (SMG-1) phosphorylates 
Upf1, SMG-5, 6 and 7 are dephosphorylating agents (Page, Carr et al. 1999; Grimson, 
O'Connor et al. 2004).  A human Upf1 dominant negative protein with an arginine to 
cystein exchange at residue 844 has been shown to reduce the targeted decay of mRNAs 
containing a PTC about two to threefold (Sun, Perlick et al. 1998).  Fusion of Upf1 to the 
mRNA binding MS2 virus protein, resembling more of a gain-of-function approach, have 
led to a destabilization effect of mRNA transcripts when including a MS2 binding 
domain (Hosoda, Kim et al. 2005).  
 
The 148 kDa adapter protein Upf2 includes binding domains for Upf1 as well as Upf3 
which are both required for NMD in mammals. With a N-terminal nuclear localization 
domain it is present both in the nucleus as well as in the perinuclear cytosol. Its essential 
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role for NMD was recently demonstrated in a conditional Upf2 knock out mouse with 
severe defects of the hematopoietic stem cells system (Weischenfeldt, Damgaard et al. 
2008). 
 
So far there is no distinct function of the NMD pathway allocated to the Upf3 protein, but 
it might be involved in the second signal response. While Upf3 is predominantly nuclear 
it is also found as a shuttle protein in the cytoplasm. Beside its Upf2 interaction domain it 
binds directly to the EJC. Interestingly the genome of mammals contains two genes 
named Upf3a on chromosome 13 and Upf3b on the X-chromosome (or Upf3 and Upf3X) 
respectively (Lykke-Andersen, Shu et al. 2000; Serin, Gersappe et al. 2001). As 
mentioned above the Upf proteins are believed to be essential for NMD and vitality. 
Despite this fact there are reports for several family lines with defective truncated Upf3b 
genes that lead to a severe phenotype of mental retardation. It might be due to at least 
partial redundancy between Upf3a and Upf3b that NMD and vitality in these individuals 
can be maintained (Tarpey, Raymond et al. 2007).  
 
 
1.2.3b Cap and PolyA binding proteins in NMD 
 
Another set of key components was found when examining the earliest events of the 
NMD pathway namely the pioneer round of translation. While the detailed mechanism of 
this very first event both in protein translation and NMD will be discussed below, the 
most important factors shall be introduced here. Freshly synthesized pre-mRNA binds 
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with its 5’ prime to a cap binding complex (CBC) consisting the cap binding protein 80 
(CBP80) and 20 (CBP20) with a rough molecular weight of 80 and 20 kDa respectively. 
Cristallography as well as extensive mutagenesis including alanine scanning contributed 
to the comprehensive picture of the CBP80/20 heterodimer. 
CBP80, similarly to elF4G, comprises of three major MIF4G domains, typical for RNA 
interacting proteins. CBP20 interacts with two of these domains while also binding RNA 
with a ribonucleoprotein domain (Mazza, Ohno et al. 2001; Marintchev and Wagner 
2005). Four residues have been identified in establishing the interface of the heterodimer. 
Especially the Y43A mutation in CBP20 proved valuable as a dominant negative protein 
disrupting the binding to RNA and therefore disturbing the function as CBC (Cusack 
2006). CBP80 proved to be essential for NMD by binding to Upf1 and promoting the 
interaction between Upf1 and Upf2 (Ishigaki, Li et al. 2001; Hosoda, Kim et al. 2005). 
The 3’ prime polyadenylated tail of the pre-mRNA interacts with the polyA binding 
protein 1 (PABP1, also called PABPC1) and 2 (PABP2, also called PABPN1). PABP2 
has been identified as the very first binding factor within the first translation round of 
newly transcribed mRNA and shows predominantly nuclear localization while PABP1 
also facilitates multiple rounds of translation through the polyribosome (Behm-Ansmant, 
Gatfield et al. 2007). Additionally PABP2 was found to be associated with CBP80 but 
not with elF4E associated mRNA (Wahle 1991; Ishigaki, Li et al. 2001).  
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1.2.4 Destined for destruction: recognition of target mRNAs for NMD 
 
The mRNA regulation cycle of NMD is mostly described as a “downstream marker 
model” emphasizing the role of the stop codon positioning within the transcript in 
determining its fate (Shyu, Wilkinson et al. 2008). In mammalian cells mRNAs that 
include a stop codon >50-55 nucleotides upstream of an exon-exon junction generated 
through the splicing of an intron are destined for NMD. Accordingly premature 
termination codons appearing closer than 50-55 nucleotides upstream to an exon-exon 
junction site will fall through the screening of NMD and will not trigger a decaying 
process (Zhang, Sun et al. 1998). This model imposes a problem when considering the 
yeast genome or for example histone genes which rarely include introns at all but are 
both sensitive to Upf1 down regulation (Maquat and Li 2001; Kaygun and Marzluff 
2005).  Also in the case of TCR gene transcripts the NMD rules for intron positioning in 
relationship to a PTC are markedly relaxed (Carter, Li et al. 1996). Here an alternative 
second signal of undefined origin has yet to be detected in order to label a particular 
mRNA for destruction. This incident is usually described as the “aberrant termination 
model” (Shyu, Wilkinson et al. 2008). The development of the NMD pathway from a 
mere PTC recognition system to a general mRNA surveillance and regulation mechanism 
of the cell has been pointedly described as a versatile transition from “a vacuum cleaner 
to a swiss army knife” (Neu-Yilik, Gehring et al. 2004). By now NMD related pathways 
include Staufen1 Mediated Decay (SMD), alternative splicing, telomere maintenance, 
mTor signaling and regulation of genome stability (Le Hir and Seraphin 2008)((Chan, 
Huang et al. 2007; Kim, Furic et al. 2007; Isken and Maquat 2008). 
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Notably Upf1 seem to play a more promiscuous role being involved in almost all of the 
described pathways while Upf2, Upf3 and CBP80/20 are mainly limited to their role in 
PTC detection mechanisms. 
 
 
1.2.5 The NMD mechanism: Pioneer round vs. bulk translation 
 
Despite the diversity of nonsense surveillance pathways they all share the requirement for 
initial translation in order to recognize a start codon and a subsequent in frame premature 
stop codon or aberrant 3’UTR. Newly synthesized and spliced mRNA is distinctly 
different from previously translated mRNA by still having the EJC deposited 20-24 
nucleotides upstream of exon-exon junctions (Le Hir, Izaurralde et al. 2000; Le Hir, 
Moore et al. 2000). Additionally nuclear mRNA assembles several other factors 
including the heterodimer CBP80/20 at the 5’cap and PABP1 and PABP2 at the 3’ 
terminus as well as elF4G as core factor of the translation complex (Ishigaki, Li et al. 
2001; Lejeune, Ranganathan et al. 2004). During this process the occurrence of a 
premature termination codon halts the EJC for a short period of time triggering the 
recruitment of Upf3 and subsequently Upf2 and Upf1 concealing the fate of the PTC 
containing mRNA for destruction. In the case of a functional mRNA transcript the first 
ribosome passing the complete gene displaces the EJC and triggers the exchange of 
CBP80/20 to elongation factor 4E (elF4E) as well as the release of PABP2 (Chiu, 
Lejeune et al. 2004). This synthesis of the very first polypeptide from a given mRNA 
transcript was named “pioneer round of translation” by the Maquat lab. No matter 
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whether the mRNA is degraded later on or serves as template for multiple rounds of 
translation, exactly one polypeptide for every newly spliced mRNA in the cell is 
synthesized within the pioneer round.  
 
The production of bulk quantities of protein facilitating polyribosomes is then carried out 
through a translation complex including elF4E, elF4G and PABP1 among many other 
factors.  While elF4G remains to take the center stage of the translation initiation 
complex, the heterodimer CBP80/20 is exchanged against elF4E which is solely used for 
bulk translation. Similar to the role of CBP80/20 the factor elF4E interacts with the 
m7GpppN 5’ terminus of mRNA subsequently unwinding the 5’UTR to provide access 
for the 40S ribosomal subunit. In mammalian cells three isoforms of 4E- binding proteins 
(4E-BP1, 2 and 3) regulate elF4E activity by binding and therefore preventing access to 
elF4G. The factor 4E-BP1 itself contains six phosphorylation sites. Only 
dephosphorylated forms of 4E-BP1 can bind to elF4E in order to down regulate bulk 
translation (Sonenberg 2008). It was demonstrated that phosphrylation sites threonine 37 
and 46 are essential for subsequent phosphorylation off all six sites. The double mutant 
T37A and T46A effectively prevents phosphorylation of 4E-BP1 and constitutively binds 
to elF4E (Burnett, Barrow et al. 1998) (Gingras, Gygi et al. 1999).  
The 4E-BP1 T37A T46A double mutant therefore became an important tool to inhibit 
elF4E dependent bulk translation while not interfering with CBP80/20 dependent pioneer 
translation. 
Bulk translation takes place at the rough ER or in association with free ribosomes in the 
cytosol. But there is a yet unsettled debate about the location of the pioneer round of 
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translation (Wilkinson and Shyu 2002; Iborra, Escargueil et al. 2004). At least in yeast 
the pioneer round of translation does not appear to take place in the nucleus 
(Kuperwasser, Brogna et al. 2004). While there are several findings supporting the 
concept of a solely nuclear translation, many results are consistent with a pioneer round 
of translation at the nuclear pore during or right after mRNA export to the cytosol (Iborra, 
Jackson et al. 2004). 
As mentioned above pioneer translation and therefore NMD require mRNA to bind the 
CBC consisting of CBP80 and CBP20. Therefore several studies addressed the question 
whether cap-independent mRNA translation initiated through an internal ribosome entry 
side (IRES) could be target for NMD. Many viruses use IRES sequences upstream of the 
start codon to attract the initial binding of a ribosome making cap-binding and polyA-
binding factors obsolete (Hellen and Sarnow 2001; Vagner, Galy et al. 2001). But 
experiments have shown that IRES vary greatly in their requirement for translation 
factors. One of the first studies addressing the minimal requirements for pioneer 
translation and NMD used a IRES derived from encephalomyocarditis virus (EMCV) 
(Holbrook, Neu-Yilik et al. 2006). Their original finding that EMCV IRES initiated 
mRNAs can undergo NMD disputes the importance of the CBC for pioneer translation. 
But a later study establishes that EMCV IRES mRNA is indeed associated to CBP80 and 
CBP20 supporting the role of the CBC in facilitating pioneer translation (Woeller, 
Gaspari et al. 2008). Finally NMD fails to target nonsense-containing transcripts that 
initiate translation from the cricket paralysis virus (CrPV) IRES (Isken, Kim et al. 2008). 
IRES from dicistroviruses like CrPV do not require any translation factors or initiator 
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tRNA in order to assemble ribosomes and initiate productive translation (Schuler, 
Connell et al. 2006).  
Taken together the CBP80/20 heterodimer proves to be the essential component of 
pioneer translation. Its counterpart during bulk translation is the 4E-BP1 regulated factor 
elF4E. 
 
 
1.2.6 Pioneer peptides as source for MHC class I mediated antigen presentation 
 
For a long time the pioneer round of translation has been merely seen as a prerequisite for 
PTC detection than as a distinct mechanism of translation. Several recent studies shifted 
the focus from the mRNA decay mechanism to understanding the occurrence and special 
features of the pioneer round of translation itself. Here NMD serves rather as an assay for 
pioneer translation than as the object of investigation. It has been determined that the 
pioneer round of translation and the biosynthesis of at least one polypeptide from each 
mRNA transcript can occur even under heat shock conditions that usually not permit 
translation (Marin-Vinader, van Genesen et al. 2006). Similarly pioneer translation 
continues under prolonged hypoxia as well as serum starvation (Oh, Kim et al. 2007; Oh, 
Kim et al. 2007). Another study positions the pioneer translation at a check point for the 
control of subsequent steady state translation under the control of  the mTOR/S6K1 
pathway (Ma, Yoon et al. 2008). These findings not only confirm that NMD appears even 
under conditions that abolish bulk translation but also opens additional possibilities for 
the cellular use of pioneer peptides. It has been shown by multiple studies as well as been 
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confirmed herein that MHC class I mediated antigen presentation directly depends on 
new translation. Since there is a continuous need for antigen presentation in the cell to 
adequately protect an organism from infection, pioneer peptides present a potential 
source of peptides for MHC class I presentation. 
 
 
1.3 Aim of the thesis research 
 
MHC class I mediated antigen presentation and NMD are two central surveillance 
pathways in the cell. The goal is to determine if NMD is involved in producing or 
altering antigenic peptides presented by MHC class molecules. This could be the case 
through two mechanisms.  
 1.) “Antigenic peptides as NMD targets” 
 In this scenario antigen encoding mRNA transcripts with a premature termination 
 codon would be degraded through the NMD mechanism leading to a reduced 
 level of surface presentation of these peptides via MHC class I molecules. 
 2.) “Peptides of the Pioneer Round of Translation as Antigens” 
 Products of the pioneer round of translation itself are cleaved by the proteasome, 
 transported by TAP, processed in the ER and presented by MHC class I on the 
 cell surface.  
Many native proteins have a live cycle of many hours to several days before they start 
being degraded and become accessible for antigen presentation. For the effectiveness of 
the immune system it is important, that virtually all cellular proteins are presented on the 
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cell surface in a rapid and continuous process. Ideally, new peptides are sampled early 
after translation before the generation of bulk quantities of proteins. Especially in the case 
of viral infections as a major challenge for the antigen presentation pathway, speed of 
presentation is a key to preventing the spreading of infections. These theoretical 
considerations found it’s match in recent experimental findings. It was shown that several 
unconventional sources of translation products are actual sources of antigenic peptides. 
These include cryptic translation products starting with non-AUG codons, peptides from 
usually untranslated regions and endocytosed or cross-presentated peptides as well as  
rejoined peptide chains. Within the last decade more and more evidence accumulated 
demonstrating the importance of freshly translated peptides as major source for antigenic 
peptides. Here the defective ribosomal products – hypothesis takes a center stage 
suggesting a subset of not completely folded proteins as immediate early antigenic 
peptides. Within the field of Nonsense Mediated Decay an unexpected source of 
translational products were discovered. This mRNA control mechanism screens for 
premature termination codons 55 or more nucleotides upstream of an exon exon junction. 
Since stop codons are only defined within an open reading frame by screening through a 
ribosome, this imposed the requirement of a pioneer round of translation of each mRNA 
prior to the onset of bulk translation. The very first round of translation is known to 
require a set of specific factors associated with the exon junction complex which are 
removed by the initial passage of the first ribosome. These pioneer round of translation 
peptides represent the first translation products of an mRNA transcript prior to the 
production of functional proteins on a large scale.  This makes them an ideal source of 
peptides for MHC class I mediated presentation without any “additional cost” to the cell 
 39 
demonstrating the synergy of two major surveillance mechanisms     -    “at the cross road 
of NMD and MHC I”.  
 
This study aims to provide independent lines of evidence for the establishment of   
“Peptides of the Pioneer Round of Translation as Antigens” as stated in option 2). Direct 
involvement of pioneer peptides in antigen presentation would add a previously unknown 
source of antigenic peptides to the repertoire of peptides presented by MHC I molecules. 
It would not only show a combined starting step of two major surveillance pathways in 
the cell but also provide a novel mechanism for the generation of immediate early 
peptides. Furthermore an answer to these questions has the potential to integrate previous 
findings about DRiPs and RDPs with new results about pioneer peptides into a combined 
picture of the origin of early translation products for antigen presentation. 
 
 
 
 
Fig.1 Origins of peptide for antigen presentation. Newly spliced mRNA assembles 
with the ribosomal subunits and factors of the pioneer round of translation before the 
onset of conventional translation for the biosynthesis of bulk quantities of peptide chains. 
New proteins are folded to their correct confirmation, serve a function as structural 
proteins or enzymes and eventually reach their live time for proteasomal degradation. 
Alternatively most defective ribosomal products (DRiPs) or cryptic translation products 
are funneled into proteasomal destruction after short time periods. Peptides from these 
different origins are transported by TAP to the ER, loaded to MHC class I molecules, 
edited by ERAAP and finally presented to T-cells at the cell surface. It has yet to be 
determined to what extent these different sources of translation contribute to the pool of 
antigenic peptides. Transport of peptides by TAP (green dotted line) and surface 
presentation (rod dotted line) are examined in this study. 
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2 Results 
 
2.1 Intron positioning and antigen presentation 
 
NMD has been described as a central mechanism insuring the fidelity of mRNA 
transcripts as well as regulating the expression of multiple genes. Two potential 
mechanisms for the interaction of NMD and MHC class I mediated antigen presentation 
have been proposed (see section 1.3: aim of this study):  
 
1.) “Antigenic peptides as NMD targets” 
2.) “Peptides of the Pioneer Round of Translation as antigens” 
 
The first hypothesis mainly suggests mRNA transcripts encoding for antigenic peptides 
as one more group of targets under the regulation of the already omnipresent NMD 
pathway. In sharp contrast the second hypothesis proposes a completely novel source of 
translation for the generation of antigenic peptides potentially explaining the importance 
of early translation for antigen presentation. 
 
The emphasis of this section is on testing the initial hypothesis 1. In general two events 
have to prelude the activation of the NMD pathway and the decay of a specific mRNA 
for any given transcript. First the premature stop codon has to be detected within an open 
reading frame through the process of the pioneer round of translation. A second signal 
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has to be recognized distinguishing the premature termination codon from a 
conventionally occurring normal stop codon. While different second signal mechanisms 
evolved in organisms as distantly related as A. thaliana and D. melanogaster the case for 
mammalian NMD signaling is made by the positioning of the intron in context of the 
premature termination codon. E Nagy established the 50-55 base pair rule: “A PTC must 
be 50-55 base pairs upstream of an intron splicing site in order to elicit NMD.” (Nagy 
Maquat 1998) This second signal rule remained to be crucial for the vaste majority of 
mammalian mRNA transcripts until today (Scofield, Hong et al. 2007). To address the 
validity of the first hypothesis several sets of expression vectors with an open reading 
frame with an antigen encoding sequence, a subsequent PTC and introns in different 
positions were generated (Fig.2). The first set of expression constructs are based on the 
invariant chain (Ii) followed by the antigen SIINFEHL (SHL8) in the vector pcDNA1. 
This construct was shown to liberate the antigenic peptide very efficiently leading to a 
particularly strong activation of B3Z T-cells upon presentation. An intron was positioned 
more than 55 base pairs down stream of the PTC (3’intron, black), completely removed 
(No intron, white) or inserted together with the splicing donor and splicing acceptor site 
upstream of start codon (5’intron, grey). An additional set of three expression vectors was 
created based on the ovalbumine residue 253-386 derived sequence kovak, including the 
Kb restricted SIINFEHL (OVA258-265) peptide. (Note: The original SIINFEKL sequence 
of ovalbumine was changed to SIINFEHL in order to make the octapeptide refractory to 
trypsin digestion, both are recognized equally by B3Z T-cells (Kunisawa and Shastri 
2003) (Paz, Brouwenstijn et al. 1999)). 
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In both cases the 3’intron constructs fulfill the requirements of a PTC 50-55 base pairs 
upstream of an intron and are therefore predicted targets of NMD. The constructs with no 
intron or an intron in 5’ position are not expected to elicit NMD.  
 
Fig.2 Antigen encoding DNA constructs with different intron positioning. Two sets 
of three pcDNA1 vector based DNA constructs were generated. The first set is based on a 
fusion protein encoding the invariant chain (Ii) and the ovalbumine derived antigen 
sequence SIINFEHL followed by a premature termination codon. The three transfection 
vectors contain an intron sequence in 3’ position (black box), no intron (white box) or an 
intron in 5’ position in front of the start codon (grey box). Only the 3’intron complies 
with the 55bp-rule making it a target for NMD. A second set of three constructs was 
designed in the same way based on the ovalbumine derived kovak sequence including the 
SIINFEHL peptide. 
 
 
2.1.1 NMD dependent mRNA regulation does not correlate with T-cell activation 
 
The above described set of three expression vectors on the basis of the kovak open 
reading frame with a 3’intron, No intron or a 5’intron were transiently transfected into 
HeLa Kb cells. The expression of kovak mRNA was determined 48 hours after 
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transfection and relative amounts were calculated using the 2-ΔΔC  method normalized to 
actin mRNA (Fig.3A) (Livak and Schmittgen 2001). In compliance with the predictions 
of NMD the 3’intron demonstrates the lowest mRNA expression level. Both the construct 
with no intron as well as a 5’intron, which lack the second signal to be recognized for the 
decay mechanism, show a 8.2 or 7.6 fold higher mRNA expression level. Next it was 
tested if these mRNA levels are also reflected in similar intensities of T-cell activation 
(Fig.3B). Here the 3’intron as well as the no intron containing kovak expression vectors 
accounted for an almost 2 fold higher B3Z T-cell response than the 5’intron sequence. 
Taken together the mRNA expression level did not seem to correlate with the T-cell 
activation rejecting a mere dependence of antigen presentation on NMD associated 
mRNA regulation.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Quantification of mRNA expression and T-cell activation. HeLa Kb cells  
were transiently transfected with a pcDNA1 vector based kovak encoding DNA construct 
including either a 3’intron (black), no intron (white) or a 5’ intron (grey). RNA was 
purified and kovak mRNA quantified by real time PCR (A). Relative kovak mRNA 
expression for each construct was determined by 2-ΔΔCT method normalized to actin 
mRNA expression. Antigenic T-cell activation of each of the three constructs was 
measured in a B3Z T-cell assay (B). 
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In order to quantify the T-cell activation based on the intron position of the Inv./SHL8 or 
kovak expression vectors two additional approaches were persued. First the vector DNA 
was transiently transfected into HEK293T cells in a 1:3 dilution series (Fig.4A and B). 
Consistent with direct T-cell presentation assays as shown in Fig.3B the relative 
relationship between contructs with no intron, a 3’intron and a 5’ intron remained the 
same.  The independent sets of expression vectors based on Inv.SHL8 and kovak 
demonstrated a  reduced B3Z T-cell activation for 5’ intron antigenic sequences. The 
peak T-cell activation for kovak based constructs appeared at a DNA transfection 
concentration of 10 ng of  DNA (Fig.4B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 DNA titration reveals differences in T-cell activation. Semiadhesive human 
HEK 293T cells were transfected with MHC Kb and B7-2 in preparation for a B3Z T-cell 
assay. Additionally they were contransfected with one of the the three Inv.SHL8 (A) or 
three kovak (B) based antigen expression vectors with different intron positions in a 1:3 
DNA dilution series. Transfection was carried out following the DEAE 
dextran/Chloroquine protocol. For both Inv.SHL8 (A) and kovak (B) based constructs 
3’intron (black) and no intron (white) vectors show a higher T-cell actvation than 
5’intron (grey) containing vectors. Untransfected cells serve as negative control (dashed). 
3’intron 
no intron 
5’intron 3’intron 
no intron 
5’intron 
kovak Inv.SHL8 A 
B 
DNA (ng) 
B3Z 
response 
(595 nm) 
 46 
Finally peptide extraction enables the by far best quantitative accessement of antigenic 
peptides generated in the cells (Fig.5). Transiently transfected HeLa Kb cells were boiled 
in 10% acetic acid for peptide extraction. After vaccum drying the purified peptides were 
added to murine K89 cells in a 1:3 titration for antigen presentation. The B3Z T-cell 
activation assay revealed the large disparity of antigen praesentation between 3’intron 
and no intron containing expression constructs with markedly high T-cell response on the 
one side, and the 5’intron constructs with T-cell activation just above the detection level 
on the other side. Generally Inv.SHL8 constructs show a higher B3Z response as kovak 
constructs. This is consistent with prior observations due to a more effiecient liberation of 
the SHL8 antigenic peptide in the Inv.SHL8 sequence. 
In conclusion the antigen expression constructs show a very distinct T-cell activation 
ability dependent on their intron position. The mRNA level by itself does not predict the 
intensity of T-cell activation. This finding cannot be deducted from the predictions made 
by the current understanding of NMD dependent mRNA regulation. 
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Fig.5 Quantification of antigen presentation after peptide extraction. For quantitative 
determination of  T-cell activation both sets of Inv.SHL8 or kovak encoding vector 
constructs were transfected into HeLa Kb cells. Peptides were extracted from 500.000 
cells each and reincubated with 100.000 K89 cells for optimal antigen presentation to 
B3Z cells. Inv.SHL8 3’intron / No intron / 5’intron (black/white/grey square) in left 
graph and kovak 3’intron, No intron, 5’ intron (black/white/grey circle) in right graph. 
Synthetic peptide SHL8 in a 1:3 titration starting at 1000 pM as positive control (dashed 
with cross), untransfected cells as negative control (black line). 
 
 
 
2.1.2 GFP based NMD-reporter constructs for antigen presentation 
 
A GFP based NMD-reporter system has been developed to monitor the activity of the 
NMD pathway in different cell lines and experimental approaches (Paillusson, Hirschi et 
al. 2005). Again the distinguishing feature between the two expression vectors is the 
presence of a 3’intron in accordance with the 50-55 base pair rule making only the first 
one a target for NMD. This approach presents several advantages in comparison to 
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previously described methods measuring mRNA levels based on RT-PCR or northern 
blotting. Monitoring GFP levels with flow cytometry enables the fast and high 
throughput analysis of NMD activity. Additionally this assay is based on the actual 
protein level allowing more direct conclusions about the amount of peptides for antigen 
presentation. The previously described NMD-reporter constructs were modified for the 
purpose of examining antigen presentation by inserting the lysine flanked SIINFEHL 
encoding sequence at the C-terminus of the EGFP protein directly followed by a stop 
codon for efficient peptide liberation (Fig.6).  
 
 
 
 
 
 
 
 
 
 
Fig.6 GFP based NMD-reporter constructs modified for antigen presentation. Both 
pCl vector constructs consist of a TCRβ leader - EGFP fusion sequence containing a 
PTC. The first contains a 3’intron making it a target for NMD (black) while the intron is 
deleted in the second construct rendering it unsusceptible to NMD (white). Comparison 
of GFP expression was used previously as measure for NMD activity. Here the sequence 
encoding the antigenic peptide SIINFEHL was inserted at the C-terminus of the EGFP in 
order to examine antigen presentation activity. 
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First the competence of HeLa Kb cells to undergo NMD was demonstrated as described 
previously in the literature (Paillusson, Hirschi et al. 2005). 100 ng of DNA of the GFP 
based NMD reporter constructs was transiently transfected into 2.5x105 cells and the GFP 
expression was determined by flow cytometry after 48 hours (Fig.7A). The total 
percentage of GFP expressing cells in the 3’intron construct accumulated to 0.78% while 
the no intron transfected cells showed 1.96% GFP positive cells. This demonstrates good 
correlation with the prediction of the 3’intron being a target of NMD. Then antigen 
presentation was determined as activation of B3Z T-cells (Fig.7B). Interestingly both 
NMD-reporter constructs demonstrated an equal level of B3Z activation independent of 
their susceptibility to NMD degradation. The T-cell response of both GFP based 
constructs was comparatively low as the control transfection with a kovak construct leads 
to a far higher B3Z activation. Low transfection efficiency of the backbone vectors 
together with a potentially less efficient peptide liberation might account for this 
generally low presentation activity. The equivocal T-cell activation of both vectors 
independent of their NMD dependent degradation underlines the findings of previous 
experiments with the Inv.SHL8 or kovak based expression vectors. As there are multiple 
steps influencing the efficiency of peptide presentation and immunodominance it can be 
difficult to pinpoint the factor responsible for the low antigenicity of the 5’intron 
constructs as well as the high antigenicity of the 3’intron construct despite the strong 
down regulation of it’s mRNA. As described before it is often not possible to reliably 
predict the immunogenicity of a given peptide sequence. But as for this case, these 
experiments taken together serve the purpose of rejecting the first hypothesis of this 
study. The NMD pathway does not just alter the antigenicity of peptides by merely 
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changing their mRNA or protein levels according to the targeting rules for mRNA decay. 
The answer may lie deeper within the mechanism of the NMD pathway as demonstrated 
by the following experiments.  
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Fig.7 GFP expression and T-cell activation of NMD reporter constructs. GFP 
expression of both NMD reporter constructs was determined in transiently transfected 
HeLa Kb cells (A). The 3’intron construct, a target of NMD, showed GFP expression in 
0.78 % of the cells (black). The NMD resistant construct lacking the intron demonstrated 
an increased level of 1.96 % GFP positive cells (white). As a negative control cells were 
transfected with a kovak encoding vector without GFP. Antigen presentation was 
accessed by B3Z T-cell assay (B). Both NMD reporter constructs showed very similar T-
cell activation independent of intron presence (right panel, black and white triangles). A 
kovak encoding vector served as positive control (left panel, cross) for T-cell activation 
and untransfected cells as negative control (dashed). 
 
 
 
 
 
 
 
2.1.3 Inhibition of pioneer translation reduces T-cell activation independent of 
intron position. 
 
Since the first hypothesis did not present a conclusive explanation of the varied 
antigenicity of different constructs, the following experiments focus on the pioneer round 
of translation by itself as an integral part of the NMD pathway and a potential source for 
the generation of antigenic peptides. The kovak based vectors with either the intron 
shuffled to the 3’ or 5’ position or the intron being deleted were transfected once more 
into HeLa Kb cells (Fig.8). Here they were cotransfected with synthetic small interfering 
RNA molecules targeting either CBP80 or Upf1. Both factors have been shown to be 
essential for the NMD pathway. Depletion of these factors results in the inhibition of the 
NMD mechanism and therefore an upregulation of mRNAs previously suppressed by 
NMD. Surprisingly, depletion of these factors led to a reduction of antigen presentation 
in all three constructs. This reduction was more pronounced for CBP80 RNAi than for 
Upf1 RNAi but independent of the intron position.  
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Fig.8 Inhibition of pioneer translation reduces T-cell activation independent of 
intron position. HeLa Kb cells were cotransfected with one of the kovak based pcDNA1 
vector constructs containing either a 3’intron (black), no intron (white) or a 5’intron 
(grey) and RNAi targeting either Upf1 (red line), CBP80 (blue line) or no RNAi (black 
line). Independent of intron position and susceptibility to NMD, Upf1 depleted cells 
showed an intermediate and CBP80 depleted cells a strong reduction in B3Z T-cell 
activation. 
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2.2 Effects of pioneer vs. cap dependent bulk translation on 
MHC class I expression   
 
Only with the discovery of nonsense mediated decay the requirement for a pioneer round 
of translation and therefore the possibility of a novel source of antigenic peptides became 
evident. This chapter aims to establish the pioneer round of translation as a separate 
mechanism of polypeptide generation as well as to demonstrate its effects on MHC class 
I mediated antigen presentation. 
 
First an assay system to differentially interfere with either the pioneer round of 
translation or with the elF4E and cap dependent bulk translation was developed (Fig.9). 
RNA interference sequences and dominant negative DNA constructs were generated 
targeting key elements of either the pioneer round or cap dependent bulk translation 
including CBP80, CBP20, PABP2, Upf1, Upf2, 4E-BP1 and elF4E. The direct effect of 
target protein depletion as well as the inhibitory function on the subsets of translation 
were determined by ways of immunoblotting and radio labeling. Two different 
approaches were taken to precisely monitor antigen presentation in tissue culture cell 
lines. In order to access the overall surface expression of MHC class I molecules, flow 
cytometry in conjunction with antibodies binding to human and murine MHC class I 
complexes was used. To track the surface presentation of specific antigenic peptides, 
different T-cell clones were used in activation assays. A citric acid based protocol for the 
removal of initial MHC class I peptide complexes and subsequent surface reassembly 
was used to determine small differences in antigen presentation. To further characterize 
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the speed and accuracy of the peptide generation their interdependence with cell cycle 
progression, cytokine levels, chemical inhibitors and starvation conditions were 
addressed. 
 
 
 
 
 
Fig.9 Differential inhibition of pioneer round of translation and bulk translation. 
Newly spliced mRNA assembles with the EJC, pioneer translation and NMD factors in 
the nucleus. The pioneer round of translation exclusively uses CBP80 and PABP2 (red) 
for initiation of translation. After the displacement of the EJC, elF4E (dark blue) 
facilitates bulk translation. 4E-BP1 (yellow) competes with the translation initiation 
complex for binding to elF4E. It therefore regulates protein biosynthesis depending on 
it’s phosphorylation stage. Factors like elF4G that are jointly used for pioneer translation 
and bulk translation are depicted in light blue. 
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2.2.1 RNAi mediated depletion of the pioneer round of translation factors CBP80, 
CBP20, Upf1 and PABP2. 
 
As described in  section 1.2.5 the pioneer round of translation includes several features 
distinguishing it from the bulk translation used for the generation of large quantities of 
cellular proteins. In order to examine the contribution of different sources of translation 
for antigen presentation, a method to exclusively target the pioneer round of translation 
was established. Translation of newly spliced mRNA transcripts is facilitated by the 
CBP80/20 heterodimer which is exchanged to eIF4E right after the first ribosome finishes 
the initial round of translation (Ishigaki, Li et al. 2001; Lejeune, Ishigaki et al. 2002; 
Chiu, Lejeune et al. 2004; Oh, Kim et al. 2007). Both proteins CBP80 and CBP20 are 
essential for this function. Additionally CBP80 promotes the interaction of Upf1 and 
Upf2. Upf1 was shown to be a factor of central importance being involved in early events 
of pioneer translation as well as being the final trigger for the mRNA decay (Hosoda, 
Kim et al. 2005). PABP2 is another protein exclusive for pioneer translation. Several 
other components like eIF4G are shared by both the pioneer as well as the bulk 
translation (Ishigaki, Li et al. 2001). Therefore CBP80, CBP20, Upf1 and PABP2 were 
targeted using interference RNA. Small interfering RNA oligonucleotides targeting the 
human sequences were designed newly or according to previously published data. 
Conditions for the transient transfection of the synthetic RNAi molecules and adequate 
down regulation of target proteins were optimized for different subclones of human HeLa 
cell cultures to develop efficient protocols. Small interfering RNA molecules targeting 
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neomycin phosphotransferase II, with a random sequence or only the lipid based 
transfection reagent without RNA molecules served as control for unspecific effects. The 
expression level of the targeted proteins was determined by immunoblot analysis. The 
protein bands were quantified in comparison to actin. The depicted immunoblots 
represent at least two independent experiments.  
 
For the small interfering RNA targeting human CBP80 (Fig.10B) and human Upf1 
(Fig.11D) a reduction of the protein level to about 25 % of the control treated cells was 
achieved. Similar depletion was achieved for CBP20 (Fig.10A) as well as PABP2 
(Fig.10B).  
 
 
 
 
 
 
 
 
Fig.10 RNAi transfection leads to reduced protein level of CBP20, PABP2 and 
CBP80. HeLa cells were transfected with small interfering RNA, cell homogenate was 
separated on 4-20% gradient SDS-PAGE gels and probed with antibodies raised against 
CBP20, PABP2 and CBP80 (A and B). Anti actin antibody served as loading control (B). 
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2.2.2 RNAi mediated inhibition of the pioneer round of translation does not effect 
the overall protein biosynthesis. 
 
Most mRNAs form polyribosome structures and undergo multiple rounds of translation 
before they reach their lifetime. Only PTC containing transcripts are limited to the 
pioneer round of translation before being degraded in a NMD dependent manner. 
Generally each newly synthesized mRNA will be translated into at least one pioneer 
round of translation product. To our knowledge there are no reports or even assays to 
determine the fate of pioneer round of translation products as unfolded polypeptide 
chains or proteins with a fully functional conformation. Taken together it can be assumed 
that the pioneer round of translation by itself only contributes very small and most likely 
undetectable quantities of protein to the overall pool of protein generated within the cell. 
In order to confirm that the RNAi mediated depletion of the pioneer round of translation 
factors CBP80 and Upf1 do not alter the overall synthesis of new polypeptides, 
radioactive incorporation assays were performed. Through radiolabeling any newly 
synthesized polypeptide chains are detected independent of length, conformation, reading 
frame or correct full-length translation. Since many of these alternative modes of 
translation might contribute to antigen generation, radiolabeling has an advantage over 
Western blotting of reference proteins that require full-length translation for antibody 
recognition. CBP80 and Upf1 RNAi depleted HeLa cells were incubated for various 
times in growth conditions including culture medium with S35 radiolabeled cysteine and / 
or methionine. Afterwards excessive radioactivity was washed of, cells were 
homogenized and peptides were loaded on a reducing SDS-PAGE gel for separation. The 
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amounts of S35 incorporation was assessed by phosphoimaging and quantified. Cells 
transfected with unrelated RNAi served as a positive control, untransfected cells treated 
with the potent translation inhibitor cycloheximide at a concentration of 100 µg/ml were 
used as a negative control.  
 
Treatment of cycloheximide led to a reduction of S35 labeled amino acids below the 
detection level of the assay. CBP80 RNAi transfected HeLa cells showed a very slight 
reduction in S35 incorporation. Cells with a reduced level of Upf1 expression 
demonstrated an increase of translation activity of about 15% in comparison to mock 
treated cells. Several studies facilitating gene chip assays demonstrated the ability of 
Upf1 to alter the expression levels of multiple genes (Mendell, Sharifi et al. 2004; Chan, 
Huang et al. 2007) . Out of 4000 genes examined after RNAi mediated inhibition of Upf1 
in HeLa cells, at least 197 genes were shown to be consistently up regulated and 176 
genes were down regulated by a factor of 1.9 or more. This effect might also account for 
the 15% increase in S35 incorporation detected here. The overall band pattern in the SDS-
PAGE gel for mock, CBP80 or Upf1 RNAi transfected cells did not show any visible 
differences indicating similar sizes of the newly generated polypeptides. Changes in the 
size distribution could have been an indicator for different efficiency of initiation or 
elongation (Fig.11A and Fig.11C). Taken together no reduction of overall protein 
biosynthesis was detected after inhibition of the pioneer round of translation neither 
through CBP80 nor Upf1. 
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Fig.11 RNAi mediated depletion of the pioneer round of translation does not effect 
the overall protein biosynthesis. Human HeLa cells were transiently transfected with 
short interfering RNA against CBP80, Upf1, neomycin phosphotransferase II (mock) or 
no RNAi. For S35 incorporation assays 2.5x105 cells were cultured for 72 h and 
radiolabeled for 40 min with methionine and cysteine under growth conditions in RPMI 
medium. Cycloheximide was used at 100µg/ml. Cells were homogenized and the 
equivalent of 100,000 cells in a 1/3 dilution series was separated on a 4-20% gradient gel. 
S35 incorporation was quantified and depicted as arbitrary units (AU) to percent of cells. 
For protein detection the equivalent of 120,000 cells for CBP80 (80kDa) and 100,000 
cells for Upf1 (137kDa) in a 1/3 dilution series were SDS-PAGE separated and 
immunoblotted. Bands were normalized to actin (43 kDa) and quantified. Data is 
representative of two or more experiments.  
 
 
2.2.3 Targeting of elF4E and 4E-BP1 reduces overall protein biosynthesis 
 
As mentioned above the shift from pioneer round of translation to bulk translation 
requires the transition from CBP80 to eIF4E. Within the steady state generation of 
protein biosynthesis eIF4E is regulated by 4E-BP1 factors. Overexpression of 4E-BP1 
has been shown to stall translation. The dominant negative mutant 4E-BP1-AA lacks the 
two residues Thr37 and Thr46 (Gingras, Raught et al. 2001). Therefore it remains 
unphosphorylated and constitutively inhibits elF4E function even more efficiently. 
Transient transfection with the dominant negative 4E-BP1-AA expression vector leads to 
a reduced incorporation of S35 methionine in comparison to cells transfected with an 
empty vector or no DNA. This inhibition was detectable after 15 min of S35 methionine 
incorporation (Fig.12A) and was even more pronounced after 120 min of translation 
(Fig.12B). Expression of the dominant negative 4E-BP1-AA vector was confirmed using 
immunoblotting. The first blot was probed with an antibody recognizing the HA-Tag of 
the 4E-BP1-AA vector. A band at 24kDa confirmed the expression of the dominant 
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negative protein. The band at 40kDa is unrelated to the experiment, the band at 43kDa a 
control transfection with the HA-tagged protein Trim21 (arrow) (Fig.12C). For an 
additional blot an antibody directly against 4E-BP1 is used. It recognized the wildtype 
protein of constitutively expressed 4E-BP1 at 22 kDa as well as the slightly larger 
transiently transfected 4E-BP1-AA at 24 kDa (Fig.12D). 
 
Alternatively elF4E can be directly targeted with small interfering RNA in order to 
achieve bulk translation inhibition. Transfection with elF4E RNAi led to a reduction of 
S35 methionine and cysteine incorporation both after 30 and 75 min of translation. The 
translation rate of cells with depleted elF4E was about 60 % of mock treated cells (Fig. 
13A and B). In order to determine the effectiveness of the small interfering RNA elF4E 
depletion was determined by immunoblotting. elF4E bands were quantified and 
normalized to actin bands demonstrating a reduction to 30 % of protein level (Fig.13C). 
 
Taken together both DNA overexpression of dominant negative 4E-BP1-AA and 
depletion of elF4E reduced bulk translation and generation of new polypeptides. 
Treatment of cells with cycloheximide at a concentration of 100 µg/ml stalled translation 
completely. 
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Fig.12 Overexpression of dominant negative 4E-BP1-AA reduces translation 
HeLa cells were transfected with a vector encoding the dominant negative 4E-BP1-AA 
sequence followed by a HA-tag or empty vector. For S35 incorporation assays cells were 
cultured for 72 h, radiolabeled for 15 min (A) or 120 min (B) with S35 methionine  under 
growth conditions in RPMI medium. Cycloheximide was used at 100µg/ml. Cells were 
homogenized and the equivalent of 300,000 cells in a 1/3 dilution series was separated on 
a 4-20% gradient gel. S35 incorporation was quantified and depicted as arbitrary units 
(AU) to percent of cells. For immunoblotting 400,000 cells were homogenized and 
loaded for separation onto a 4-20% SDS-PAGE gel in a 1/3 dilution series. The blot was 
probed with antibody raised against the HA-tag of the 4E-BP1-AA protein. 4E-BP1-AA 
was detected at 24 kDa, a control transfected Trim21 protein at 43kDa (C). Additionally 
constitutive wt 4E-BP1 as well as transiently transfected 4E-BP1-AA was detected 
directly (D). 
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Fig.13 RNAi mediated depletion of translation factor elF4E reduces protein 
biosynthesis.  HeLa cells were transfected with RNAi against eIF4E of random sequence 
RNAi. For S35 incorporation assays cells were cultured for 72 h, radiolabeled for 30 min 
(A) or  75 min (B) with S35  methionine  under growth conditions in RPMI medium. 
Cycloheximide was used at 100µg/ml. Cells were homogenized and the equivalent of 
150,000 cells in a 1/3 dilution series was separated on a 4-20% gradient gel. S35 
incorporation was quantified and depicted as arbitrary units (AU) to percent of cells (A 
and B). For immunoblotting 200,000 cells were homogenized and loaded for separation 
onto a 4-20% SDS-PAGE gel in a 1/3 dilution series. The blot was probed with antibody 
against elF4E (25kDa) and actin (43 kDa) for normalization (C). 
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2.2.4 Depletion of Upf1 reduces surface presentation of MHC class I  
 
In the previous paragraphs a differential strategy to inhibit either the pioneer round of 
translation or the bulk synthesis of polypeptides was established.  It was demonstrated 
that pioneer translation does not have a detectable effect on the overall generation of 
polypeptides. Several known sources of translation including cryptic translation and 
DRiPs are not contributing to the general synthesis of proteins while they play an 
important role in producing antigens for MHC class I mediated presentation (Shastri, 
Schwab et al. 2002). Here it shall be tested, if depletion of factors essential for the 
pioneer round of translation have any effect on the cell surface presentation of MHC class 
I. When MHC class I molecules that are loaded with their matching antigenic peptides 
finally reach the cell surface, they went through a cascade of rigorous steps optimizing 
the quality and binding properties of the peptides. They usually have a KD of  more than 
500 nM and stably remain on the cell surface for hours or even days (Yewdell 2006). 
Therefore changes in the supply or processing of peptides often do not directly result in 
alterations of the MHC class I levels on the surface. Previously a method was established 
to extract the peptides from the binding cleft of the MHC class I molecule on the cell 
surface (Kunisawa and Shastri 2003). This is achieved with an acid wash procedure with 
PBS buffered citric acid at pH 3.1 for 1 to 5 minutes immediately followed by several 
steps of PBS rinsing. Conditions were adapted for several cell lines as well as murine 
primary cells. Adhesive cells remain attached to the culture dish during the acid wash 
treatment allowing for good conditions for continuous growth and culture of the cells. 
Removal of the peptide leads to the reinternalization and recycling of the heavy chain. 
 65 
The β2m chain, which is only non-covalently attached to the heavy chain, is permanently 
removed through the washing procedure. Within a time course of several hours newly 
generated MHC class I molecules are loaded and presented at the cell surface. The time 
of surface recovery is highly dependent of the cell line as well as the specific MHC class 
I peptide complex and has to be adjusted for the experimental conditions. Significant 
differences in the recovery times even for different subclones of the same cell line were 
observed. Generally the time for complete recovery ranges between 4 and 10 hours with 
murine MHC Db being relatively fast and MHC Kb being slightly slower in achieving full 
recovery. In addition to respective primary and secondary antibodies, cells were stained 
with propidium iodine to select only living cells for analysis. Propidium iodine positive 
cells, generally a population of less than 0.5% of the cells that remain after citric acid 
washing, were excluded form the analysis.  
Here human HeLa cells stably transfected for the murine MHC class I molecule Kb as 
well as for the ovalbumine derived antigen precursor Kovak were used. They allow 
monitoring of the human HLA A, B and C as well as the murine Kb MHC class I 
molecules during the acid wash recovery experiments. Cells were depleted for Upf1  
using small interfering RNA, peptides were removed through acid wash treatment, and 
cells were placed under growth conditions for various times from 0 to 6 hours (Fig.14A 
and B). After both 3 and 6 hours a significantly reduced level of Kb surface expression 
was detected (Fig.14A). This observation was also consistent with a lower level of 
surface HLA A, B and C (Fig.14B). This observation was consistent in more than 10 
experiments. General RNAi mediated depletion of Upf1 was confirmed with 
immunoblotting (Fig.14C). Since western blotting can only demonstrate an overall 
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reduction of Upf1 in a pool of homogenized cells, Upf1 protein levels were additionally 
accessed on a per cell basis using flow cytometry. Cellular Upf1 protein levels were 
reduced in all permeabilized cells as demonstrated by the shift of the graph for Upf1 
RNAi treated cells to the left (Fig.14D, red line). Unpermeabilized cells served as a 
control for Upf1 specificity. 
Together these experiments indicate a loss of MHC class I surface presentation in Upf1 
depleted cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.14 Transient depletion of Upf1 reduces the surface presentation of MHC class I. 
HeLa Kovak/Kb cells were transiently transfected with RNAi targeting Upf1 (red), 
neomycin phosphotransferase II (orange) or no RNAi (grey shadow). Cells were 
untreated (no acid wash) or acid washed and placed under culture conditions for various 
times 90, 3, 6h). MHC surface levels were monitored by flow cytometry using primary 
antibody 5F1.2.14 against Kb or W6/32 (A) against HLA A, B, C (b). RNAi mediated 
depletion of Upf1 was confirmed by immunoblotting (C) and flow cytometry (D). Cells 
were permeabilized with -20°C prechilled EtOH and stained for internal Upf1 protein 
levels.   
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2.2.5 Reduction of PABP2 expression leads to intermediate MHC class I surface 
recovery 
 
 
PABP1 and PABP2 have been described as protein factors present at the translation 
initiation complex of newly spliced mRNA (Ishigaki, Li et al. 2001). After the pioneer 
round of translation PABP2 is removed from the assembly, while PABP1 remains bound 
to the Poly-A tail of the mRNA facilitating further rounds of translation. Here the effect 
of PABP2 depletion on MHC class I surface expression was directly compared to the 
previously demonstrated Upf1 mediated MHC class I surface reduction (Fig.15). As 
described in the experiments above HeLa Kovak/Kb were transfected with small 
interfering RNA molecules, treated with citric acid solution for the removal of initial 
MHC class I surface molecules and recovery was monitored over a 6 hour time interval. 
Flow cytometric determination of the MHC class I HLA A, B, and C surface expression 
levels showed a clear difference in recovery between Upf1 depleted cells on the one hand 
and irrelevant neomycin phosphotransferase II RNAi or untransfected cells after 3 hours. 
Absolute numbers of mean fluorescence for the 3h time point were 24.8 for Upf1, 29.4 
for PABP2, 42.4 for Neo and 41 for no RNAi. Therefore cells with a reduced PABP2 
level showed an intermediate phenotype with HLA A, B and C levels lower than control 
transfected cells but slightly higher than Upf1 diminished cells. After 6 hours the absolute 
differences were less pronounced while the same relative differences between Upf1, 
PABP2, Neo and untransfected cells remained (Fig.15A). Analysis of Kb surface 
expression presented similar findings at the 3 and 6 hour time points with more 
pronounced MHC class I reduction for Upf1 and intermediate MHC class I reduction for 
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PABP2 depleted cells. While this pattern was consistent in at least two independent 
experiments there remain several explanations for an intermediate effect of PABP2 
depletion on MHC class I surface recovery. These include more technical findings like a 
less pronounced efficiency of the small interfering RNA transfection in reducing the 
PABP2 target protein level or more functional explanations like a less stringent 
requirement for PABP2 or a redundancy between PABP1 and PABP2 in facilitating the 
pioneer round of translation mechanism. Since it might be difficult to conclusively 
distinguish between these possibilities, further experiments focused on additional factors 
of the pioneer round of translation with more pronounced effects. In summary PABP2 
reduction shows intermediate inhibition of MHC class I surface expression.  
 
 
Fig.15 Transient depletion of PABP2 reduces the surface presentation of MHC class 
I to a lesser extent than Upf1. HeLa Kovak/Kb cells were transiently transfected with 
RNAi targeting PABP2 (green), Upf1 (red), neomycin phosphotransferase II (orange) or 
no RNAi (grey shadow). Cells were acid treated as described above. MHC surface levels 
were monitored using primary antibody or W6/32 (A) or 5F1.2.14 (B). Depletion of 
PABP2 reduced the recovery of both HLA A, B and C as well as Kb but to a lesser extent 
than Upf1 depletion. 
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2.2.6 Depletion of the pioneer round of translation factor CBP80 reduces surface 
presentation of MHC class I  
 
CBP80 has been described as the defining protein for the pioneer round of translation. 
Jointly with CBP20 it interacts with the cap structure of the newly spliced mRNA as well 
as elF4G (Marintchev and Wagner 2005). Since it is removed from the translation 
initiation complex right after the first passage of the ribosome it is the ideal target to 
demonstrate the involvement of the pioneer round of translation in antigen presentation 
(Lejeune, Ishigaki et al. 2002; Chiu, Lejeune et al. 2004). This represents an advantage 
over experiments focusing solely on Upf1, which has been demonstrated to be part of the 
pioneer translation but also takes part in final processes of mRNA decay as well as 
general gene regulation (Mendell, Sharifi et al. 2004; Chan, Huang et al. 2007). 
 
Additionally, a subclone of HeLa cells (termed AS1) were used which showed a 
particularly slow MHC class I surface recovery pattern. After surface removal these cells 
only regain their prior level of MHC class I expression after about 8.5 hours. This helps 
to examine any differences of MHC class I recovery times of cells deficient for the 
pioneer round of translation. Cells were transfected with small interfering RNA 
molecules, washed with citric acid buffer and placed under culture conditions as 
described above. After initial optimization experiments flow cytometry analysis was 
performed in a time course with measuring intervals prior to acid wash, right after acid 
wash and at 7.5 and 8.5 hours of culture. CBP80 as well as Upf1 depleted cells showed a 
very similar or slightly reduced overall MHC class I level as assessed with antibody 
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W6/32 (Fig.16A). Acid wash completely removed MHC class I complexes reducing the 
mean fluorescence in all cases to the level of only secondary antibody staining. After 7.5 
hours 42 % of untransfected cells recover to their level of MHC class I surface expression 
prior to acid wash. At the same time only 9-11% of the Upf1 or CBP80 depleted cells 
show full MHC class I expression. This disparity remains at the 8.5 hour  the time point 
with 85 % of control cells fully recovering their HLA A, B and C expression. In 
comparison only 38 and 40 % of CBP80 and Upf1 depleted cells recover at this time 
interval. The separate panel line shows the recovery pattern at the 8.5 hour time point 
with absolute numbers of cells on the y-axis as well as the gate (box with arrow) used for 
the determination of the percentage of fully recovered cells. 
Assembly of functional MHC class I molecules on the surface requires the noncovalent 
binding of β2m with the heavy chain as well as association with an appropriate peptide. 
Therefore the overall surface expression of MHC class I complexes can be determined by 
flow cytometric measurement of β2m (Fig.16B). Also here the recovery follows a similar 
pattern with only 13 and 16 % of Upf1 and CBP80 depleted cells in comparison to 55% 
of untreated cells with full β2m surface expression after 7.5 hours. After 8.5 hours the 
difference between 43 and 41 % of Upf1 and CBP80 transfected cells to 83% of control 
cells regaining their prior β2m levels remains large. Targeting of CBP20 results in a 
comparable delay of MHC class I expression after acid wash confirming above findings 
and ruling out unspecific or off target effects of the small interfering RNA molecules. 
While the underlying reasons for the bimodal MHC class I recovery pattern were 
addressed in additional experiments, CBP80 expression and the pioneer round of 
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translation can be postulated as an essential requirement for timely MHC class I surface 
presentation. 
 
 
 
 
Fig.16 Bimodal distribution of MHC class I surface expression in Upf1 and CBP80 
depleted HeLa cells. MHC class I surface recovery is cell line dependent. A subclone of 
HeLa cells were transiently transfected with RNAi targeting Upf1 (red), CBP80 (blue) or 
no RNAi (grey shadow). MHC class I surface recovery was accessed after 0, 7.5 and 8.5 
h using antibody against HLA A, B and C (A) or beta2m (B). MHC class I surface level 
is depicted in relative and for the 8.5h time point additionally in absolute cell numbers. A 
gate was chosen for cells with fully recovered MHC levels (square box with arrow) and 
the percentage of cells recovered at each time point were depicted in separate diagrams 
(bottom).  
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2.2.7 RNAi mediated depletion of CBP80, CBP20 and Upf1 decreases activation of 
three different T-cell lines. 
 
The previous sections postulate a reduced number of MHC class I molecules in cells 
transiently depleted of the pioneer round or translation factors CBP80 and Upf1. MHC 
class I levels were assessed as total amount of Kb or HLA A, B and C molecules on the 
surface recognized by specific antibodies. In order to determine the effect of a diminished 
pioneer round of translation on the generation and surface presentation of specific 
antigenic peptides acid wash recovery experiments were performed with subsequent T-
cell activation assays (Fig.17). HeLa Kovak/Kb cells were RNAi transfected and citric 
acid treated for MHC class I surface removal as described before. Afterwards cells were 
placed under culture conditions for recovery of MHC class I surface expression for 0, 3 
and 6 hours. Peptides were extracted from 500,000 cells of each condition resuspended 
and titrated in a 1 to 3 dilution series (see methods 4.9). Peptides were incubated with 
100,000 HeLa Kb cells as antigen presenting cells and 100,000 B3Z T-cells. B3Z cells 
recognize the Kb restricted ovalbumine derived antigen SIINFEHL. After 16 hours T-cell 
activation was measured in a CPRG assay (Fig .17).  
In the absence of SIINFEHL antigen, HeLa cells are not capable of triggering any B3Z 
specific response serving as a negative control for the assay (black line at bottom). Upf1 
depleted cells (red) show as similar or slightly increased rate of T-cell activation in 
comparison to untransfected (black) or neomycin phosphotransferase II (orange) control 
transfected cells at all time points. In sharp contrast to that, the initial absorbance of 
CBP80 (blue) depleted cells of 0.8 prior to acid wash was reduced to 0.12 right after acid 
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treatment and only recovers slowly to 0.37 after 3 hours and 0.58 after 6 hours. Therefore 
antigen presenting HeLa cells are only capable of triggering a B3Z T-cell response of 
about half the intensity of control-transfected cells.  This finding goes along with 
previous observations of a reduced MHC class I surface expression in CBP80 deficient 
cells as detected by flow cytometry. It underlines the importance of pioneer factors for 
efficient antigen generation and surface presentation. The unaltered or even slightly 
increased T-cell activation of Upf1 depleted cells might find its explanation in the 
multiple roles of Upf1 in altering gene expression of many genes. In conclusion this 
experiment has demonstrated the dependency of MHC class I surface presentation on 
CBP80 pioneer translation for at least one specific antigen. Additionally it should be 
underlined that with this experimental design extracting antigenic peptides and presenting 
them separately through different cells, unspecific effects of the RNAi treatment on MHC 
class I maintenance or regulation can be ruled out.  
 
Two additional T-cell lines were used in a similar experimental setup in order to 
substantiate these results. Small interfering RNA transfection for CBP80 (blue), CBP20 
(green), Upf1 (red), neomycin phosphotransferase II (orange) and no RNA as well as acid 
wash were performed as described above (Fig.17). Here 100,000 HeLa Kovak/Kb cells 
were used in a direct presentation assay. Brefeldin A was added in the concentration of 
5µg/ml in order to prevent any further Golgi transport of MHC class I peptide complexes 
during the incubation with the T-cells. For activation assays the T-cell lines 18.5Z and 
27.5Z were used in addition to B3Z. Both recognize a specific antigen of unknown 
sequence. In accordance with the previous experiment (Fig.17) Upf1, Neo and no RNAi 
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transfected cells show similar B3Z T-cell activation both after 5 and 6.5 hours. CBP20 
RNAi transfected cell demonstrate an intermediate T-cell response in the CPRG assay 
while CBP80 RNAi transfected cells lead to a markedly reduced B3Z activation. In a 
similar way CBP80 depletion leads to a severely reduced 27.5 T-cell activation. Here 
Upf1 as well as CBP20 reduction goes along with a T-cell response less than half of the 
control samples. This is consistent with 18.5 T-cell activation with the lowest activation 
of CBP80 RNAi treated cells, slightly increased responses of Upf1 and CBP20 RNAi 
treated cells. Consistent with all experiments CBP80 deficient antigen presenting cells 
demonstrate a markedly reduced T-cell recognition further confirming measurements of 
overall MCH class I surface levels as determined by antibodies and flow cytometry. 
CBP20 and Upf1 RNAi transfection seem to have a lesser effect on antigen presentation. 
Interestingly Upf1 reduction altered the 18.5Z and 27.5Z peptides to a larger extent than 
the B3Z recognized SIINFEHL peptide. 
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Fig.17 Peptides extracted from CBP80 depleted cells show reduced B3Z T-cell 
activation. HeLa Kovak/Kb cells were transfected with RNAi targeting CBP80 (blue), 
Upf1 (red), Neo (orange) or no RNA (black). After citric acid wash cells were placed 
under culture conditions for 0, 3 or 6 h. Peptides were extracted from 500,000 cells and 
presented by HeLa Kb cells to B3Z T-cells for CPRG assay measurement. CBP80 
depleted cells demonstrate lower B3Z T-cell activation after 3 h. 
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Fig.18 CBP80, CBP20 and Upf1 depleted cells show reduced activation of three 
different T-cell lines. HeLa Kovak/Kb cells were transfected with RNAi targeting 
CBP80 (blue), CBP20 (green), Upf1 (red), Neo (orange) or no RNA (black), washed with 
citric acid buffer and cultured for 5 or 6.5 h for MHC class I surface recovery. 100,000 
cells each were used in CPRG T-cell assays with the cell lines B3Z, 27.5Z or 18.5Z in the 
presence of brefeldin A. T-cell activation was determined as absorbance at 595nm. The 
T-cell response for all three cell lines is strongly diminished in CBP80 depleted cells and 
to some extend reduced in CBP20 depleted cells. Upf1 depleted cells show only a 
reduced T-cell activation for 18.5Z and 27.5Z while leaving B3Z recognition unaffected. 
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2.2.8 Permanent Upf2 reduction lowers MHC class I expression  
 
Nonsense mediated decay is required for viability at an organismal as well a cellular 
level. Attempts to generate an Upf1 knock out mouse model were doomed by the early 
embryonic lethality of Upf1 deficient cells (Medghalchi, Frischmeyer et al. 2001). Here 
the requirement of Upf1 even prevented the generation of cell lines with permanently 
diminished factor expression. Cell lines stably transfected with Upf1 targeting small 
hairpin RNA sequences incorporated within an puromycin selectable expression vector 
did not generate any stable cell lines viable after 10 days (Wittmann, Hol et al. 2006). In 
contrast two functional and partially redundant Upf3 homologues are encoded in 
mammals. In humans dysfunctionality in one of these genes is tolerated even though it is 
manifested in a severe disease phenotype (Tarpey, Raymond et al. 2007). This leaves 
Upf2 as potential target for stable down regulation via vector encoded small hairpin RNA 
(Wittmann, Hol et al. 2006). HeLa cells were selected for stable incorporation of the 
Puro-Upf2-shRNA construct by culturing in the presence of 10 µg/ml puromycin and 
reduced Upf2 protein expression was confirmed by immunoblotting. The two HeLa cell 
line subclones shown below were provided by Juergen Wittmann and Hans-Martin Jaeck 
(Fig.19). Both independent clones show permanently about 5 fold reduced MHC class I 
levels as recognized by staining with antibody W6/32. The total combined cellular and 
surface amount of MHC heavy chain in both Upf2 diminished subclones as well as 
control cells was additionally assessed by immunoblotting using antibody HC10. The 
Western blot confirmed the overall reduction of heavy chain. Since the MHC class I 
molecule is only stable in the confirmation bound to an antigenic peptide these findings 
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are another indicator for the lack of sufficient antigen generation in the absence of Upf2. 
While this is so far the only example of a viable mammalian cell line with permanently 
reduced expression of a factor of the pioneer round of translation and NMD pathway, 
there will likely be more cell lines and primary cells originating form a recently 
established Upf2 conditional knock out mouse.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19 Stable depletion of Upf2 reduces both MHC class I surface and internal HC 
levels. HeLa cells were transfected with a shRNA vector targeting Upf2. Subclones with 
stable down regulation of Upf2 were selected for further analysis. MHC class I surface 
expression was determined by flow using antibody W6/32. Total heavy chain expression 
was measured using immunoblotting with antibody HC10. 
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2.2.9 Short time intervals of new translation are sufficient for antigen presentation 
 
It was demonstrated that ongoing translation is a requirement for antigenic peptide 
generation and presentation (Qian, Reits et al. 2006). In order to examine the minimum 
requirements of translation for antigen production cycloheximide was used in a time 
course experiment (Fig.20). HeLa cells were treated for 2 hours prior to the acid wash 
removal to ensure that recently translated polypeptides are already processed and 
transported to the surface. MHC class I surface molecules were removed with citric acid 
and cells were permitted to recover for various time intervals from 0 to 60 min to 
progress with translation. After that translation was again interrupted by addition of 
cycloheximide and cells were cultured for a total of 6 hours followed by flow cytometry 
analysis using antibody W6/32. As expected cells that were continuously exposed to 100 
µg/ml cycloheximide were not able to translate peptides for presentation. While 2 
minutes were not sufficient, 8 or more minutes of translation generated peptide MHC 
class one complexes detectable on the surface. This confirms the dependency of antigenic 
peptide generation on new translation. Further it demonstrates that the very first peptides 
generated within several minutes already contribute to antigen presentation. 
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Fig.20 Minimum time requirement for peptide generation. HeLa cells were pretreated 
with 100 µg/ml CHX for 2 h prior to acid wash. Cells were placed in recovery conditions 
for time intervals of 0-60 min before interruption of translation with CHX. MHC class I 
surface recovery was determined 6 h after citric acid treatment by flow cytometry using 
antibody W6/32. Permission of 8 min of translation is sufficient for the generation of 
peptides presented on the cell surface. 
 
 
2.2.10 Inhibition of bulk translation does not effect antigen presentation 
 
Multiple rounds of elF4E-dependent bulk translation of mRNA transcripts account for the 
generation of the waste majority of proteins in a cell. Here it shall be examined if a 
reduction of this steady state translation pathway has any measurable effect on antigen 
generation and MHC class I mediated surface presentation. In the first experiment 
inhibition of bulk translation has been achieved as described above. HeLa Kovak/Kb cells 
have been transfected with the dominant negative 4E-BP1-AA vector construct (red), the 
wildtype 4E-BP1 DNA (orange), an empty vector (yellow) or no DNA (grey shadow 
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(Fig.21 A and B). Additionally cells were incubated with cycloheximide at the 
concentration of 100 µg/ml (black). Cycloheximide interferes with the translocation 
therefore abolishing all translation elongation. MHC class I surface expression was 
monitored by flow cytometry analysis using antibodies W6/32 and 5F1.2.14. All cells 
transfected with any of the vector constructs showed some MHC class I upregulation. 
This is an unspecific effect apparently related to transfection itself. No differences in 
MHC class I surface expression between the 4E-BP1-AA, 4E-BP1 or empty vector 
constructs were detected after 3 and 6 hours. Even though 4E-BP1-AA transfection has 
been demonstrated to significantly reduce the amount of newly generated polypeptide 
chains it did not impose any detectable effect of MHC class I mediated antigen 
presentation. In stark contrast cells with cycloheximide regained only initial surface 
expression at the 3 hour time point. No further MHC class I reappearance was measured 
after 6 hours. The initial recovery might be due to the time required for cycloheximide to 
enter the cell, bind to the ribosomes and stall new translation initiation. During this time 
period recently loaded MHC-peptide complexes can continue to progress on their passage 
from the ER through the Golgi to the cell surface independent of cycloheximide. So 
inhibition of overall translation proofed to be a very effective measure to abolish peptide 
generation and presentation. This finding is supported by the strict requirement of 
ongoing translation for antigen generation (Qian, Reits et al. 2006).  
 
Additionally it was demonstrated that the MHC class I heavy chain is abundantly present 
during the course of the experiment (Fig.21 C). With a relatively long protein half-life the 
heavy chain is continuously present during 4E-BP1-AA expression. Cycloheximide 
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incubation only gradually decreases the overall pool of heavy chain after 2 hours. Even 
after 1 and 2 days of cycloheximide treatment at 100 µg/ml substantial amounts of heavy 
chain can be detected by immunoblotting. Therefore the availability of heavy chain does 
not seem to be the reason for stalled MHC class I surface presentation but rather the 
interference with the generation of new peptides. 
 
4E-BP1-AA binds to elF4E therefore preventing it from functioning in bulk translation. 
Alternatively small interfering RNA against elF4E can prevent the assembly of the 
initiation complex for bulk translation. HeLa AS1 cells with depleted elF4E were shown 
to recover their MHC class I surface level in the same pattern as untransfected cells. Both 
elF4E depleted and control cells recover to 23.3 and 25.1 % after 7.5 hours and to 60.5 
and 59.2 % respectively after 8.5 hours. No significant effect on MHC class I surface 
presentation could be detected upon reduced elF4E expression and bulk translation. 
 
Taken all these findings together, antigen presentation remains to be dependent on the 
active and ongoing translation of RNAs. Alterations of the elF4E dependent bulk 
translation do not change antigenic peptide generation. It has to be considered that bulk 
translation usually produces large quantities of polypeptides and that even a very 
effective RNAi targeting strategy is unlikely to completely abrogate bulk translation, 
particularly the relatively small copy numbers needed for the MHC class I mediated 
antigen presentation. But on the other hand these finding continue to underline the 
importance of the pioneer round of translation for antigen generation, which might just 
generate minuscule amounts of peptides while altering antigen surface levels severely. 
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Fig.21 Inhibition of 4E-BP1 regulated bulk translation does not alter MHC class I 
expression. HeLa Kovak/Kb cells were transiently transfected with no DNA (grey 
shadow) or DNA constructs encoding dominant negative 4E-BP1-AA (red), wildtype 4E-
BP1 (orange) or empty vector (yellow). 100 µg/ml cycloheximide was added in the 
recovery medium to inhibit overall translation (black line). After acid wash flow 
cytometric analysis was performed using antibody W6/32 (A) and 5F1.2.14 (B). No 
apparent effect of 4E-BP1AA or 4E-BP1 wt on MHC class I recovery was detected. 
Additionally cells were transfected with 4E-BP1-AA or incubated with cycloheximide for 
various times between 2 and 72 hours as indicated. The equivalent of 100.000 cells or a 
subsequent dilution 1/3 was loaded on a 4-20% SDS-PAGE gradient gel and probed for 
MHC class I heavy chain expression.  
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Fig.22 Inhibition of elF4E dependent bulk translation does not alter MHC class I 
expression. HeLa AS1 cells were transfected with elF4E (purple) or no (grey shadow) 
RNAi, acid treated and cultured for 0, 7.5 and 8.5 hours before staining with antibody 
against ß2m to access total MHC class I surface levels. MHC class I expression is 
depicted as percentage of cells with completely regained surface expression (box, table & 
graph). Both elF4E and control cells recover MHC class I levels to equal extent after 7.5 
and 8.5 hours. 
 
 
 
 
2.2.11 Bimodal distribution of MHC class I recovery in HeLa AS1 cells 
 
In multiple experiments a bimodal recovery pattern as depicted in Fig.22 was observed. 
Two distinguishable peaks became particularly visible with a large difference between 
the maximum fluorescence labeling before acid wash and the minimum right after acid 
wash. Cells like HeLa AS1 with a relatively slow surface recovery of MHC class I 
molecules show very distinctive peaks. Since these experiments take an important 
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position within this study the recovery pattern of subpopulations was studied in more 
detail. Three factors were identified that could potentially account for differences in 
MHC class I expression between these subpopulations. 
 
1.) Transfection efficiency of small interfering RNA is different for MHC class I high 
and low expressing cells 
2.) RNAi mediated down regulation of target proteins differs in subpopulations 
3.) Differences in the stage of the cell cycle account for bimodal MHC class I surface 
reappearance. 
 
First it was confirmed that small interfering RNA transfection was equally efficient for 
the different subsets of cells. HeLa AS1 cells were cotransfected with Upf1 RNAi and an 
equal amount random sequence RNA of the same length with a red fluorescence tag. The 
cells were then used for an acid wash recovery experiment and analyzed by flow 
cytometry for the surface expression of HLA A, B and C as well as the uptake of red 
fluorescence from the control RNA. The red fluorescence was determined for each time 
point before acid treatment and at 0, 8 and 9 hours of culture for the entire peak (red) as 
well as separately for the 50% cells with lower (blue) and higher (green) MHC class I 
expression. All cells transfected with RNAired showed high level of red fluorescence 
confirming the RNAi uptake of almost 100% of the cells. RNAired transfection levels 
were comparable between MHC class I low (blue) and high (green) expressing cells 
within a significant increased above control cells (grey) in mean red fluorescence.  
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Fig.23 RNAi transfection efficiency consistent in subsets of recovering cells. HeLa 
AS1 cells were cotransfected with equal amounts of Upf1 and red fluorescence labeled 
random sequence RNAi, washed with citric acid and cultured for 0, 8 or 9 hours. MHC 
class I expression was probed with W6/32 staining (left). RNAred uptake was analyzed for 
the total amount of cells (red), 50 % cells with lowest MHC class I expression (blue) and 
50 % with highest MHC class I expression (green) (right). All subsets of cells 
demonstrated RNAred uptake.  
 
 
 
 
Further the interdependence of MHC class I surface expression and the cell cycle was 
addressed. As noted before new generation of MHC class I peptide complexes requires 
ongoing protein translation. Within the progression of the cell through the cell cycle 
different subsets of translation are more ore less active. During cell division global cap-
dependent protein translation is slowed down by stalling the ribosomes in the elongation 
step while IRES dependent translation of many cytokines and mitosis factors is up 
regulated (Sivan, Kedersha et al. 2007) (Pyronnet, Pradayrol et al. 2000). Due to the 
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differential regulation of these modes of translation, a potential correlation between MHC 
class I surface recovery and the cell cycle progression was examined. HeLa AS1 cells 
were transfected with Upf1 (red) or no (grey shadow) small interfering RNA and acid 
treated (Fig.24).  Cells were stained at different time points during their recovery with 
antibody W6/32 (left panel). The cell permeable propidium iodine was added as DNA 
marker to determine the cell cycle stage (right panel). The DNA content is depicted as 
linear propidium iodine staining with the G1 phase corresponding to 2 n, the G2 phase 
with 4 n and S phase with an intermediate set of chromosomes between 2 and 4 n. The 
propidium iodine stained DNA content was determined for the total of recovering cells as 
well as for the 50 % cells with lower or respectively higher MHC class I surface 
expression. Cells with low levels of surface MHC class I were predominantly in the G1 
phase while cells with higher MHC class I expression progressed to a larger extent from 
G1 through S to G2. This effect has been consistent in three independent experiments in 
HeLa cell as well as murine K89 cells. It is consistent with additional experiments using 
the DNA staining reagent Hoechst 33342 in fixed cells in order to measure cell cycle 
progression. No significant difference between Upf1 RNAi or untransfected cells could 
be detected in this experimental approach. Human Upf1 has been recently described to 
interact with DNA synthesis and DNA damage response during S-phase progression 
(Azzalin and Lingner 2006). Since this could not be confirmed for Upf2 or in non human 
cell lines it might be an effect depending rather on some Upf1specific gene regulation 
than on NMD or pioneer round of translation in general. While the correlation of cell 
cycle stages and MHC class I surface expression might be interesting for further 
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experimentation it does not explain reduced antigen presentation upon pioneer round of 
translation inhibition. 
 
 
 
 
 
Fig.24 MHC class I surface recovery correlates with cell cycle progression 
HeLa AS1 cells were transfected with Upf1 (red) or no RNAi (grey shadow), washed 
with citric acid, cultured for 0, 8 or 9 hours and analyzed with antibody W6/32 staining 
(left). Staining with propidium iodine for DNA content was used to determine cell cycle 
stage for the total of cells as well as the 50 % cells with lowest and highest MHC class I 
expression (right). Lower MHC class I correlates with predominantly G1, higher MHC 
class I with progression from G1 through S to G2. No significantly different cell cycle 
stage could be detected for Upf1 of no RNAi transfected cells.  
 
 
 
 
 
2.2.12 Effect of Interferon β on MHC class I surface expression 
 
The cellular response to viral infection and the recognition of foreign RNA often includes   
an induction of interferon type I as well as a subsequent upregulation of several immune 
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functions including MHC class I expression and antigen presentation. Transfection with 
small interfering RNA has been suspected by several authors to include off-target effects 
including unspecific gene regulation and activation of an interferon response 
(Tschaharganeh, Ehemann et al. 2007; Stewart, Li et al. 2008). Therefore especially 
RNAi strategies targeting immune functions under the control of interferon have to be 
well controlled demonstrating not only depletion of the target protein but also excluding 
any additional effects due to cellular RNA recognition. Transfection with different RNA 
sequences against the same factor, random sequence RNAi constructs, constructs 
targeting irrelevant neomycin phosphotransferase, synthetic RNA molecules or vector 
encoded small hairpin RNA as well as different transfection reagents have been included 
in previous experiments as lines of precaution.  
Here the dependency of murine Kb MHC class I surface recovery on pioneer round of 
translation factor Upf1 was examined in the presence of interferon β  (Fig.25). HeLa 
Kovak/Kb cells were transfected with no, Neo or Upf1 small interfering RNA and treated 
with citric acid for MHC class I surface recovery analysis. Cell culture medium included 
500u/ml of human interferon β. During a fully activated interferon β response cells 
recovered as observed before with Upf1 depleted cells (red) showing a reduced MHC 
class I surface reappearance after acid wash. In comparison cells transfected with the 
different synthetic RNAi molecules but without the addition of interferon β generally 
expressed lower levels of MHC class I while recovering in the same pattern (thin gray 
lines). In conclusion interferon β stimulation does not change the requirement of pioneer 
translation for fast MHC class I surface expression. 
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Fig.25 Effect of interferon β  on MHC class I expression. Comparison of murine MHC 
class I Kb surface expression in the presence or absence (thin grey lines) of 500u/ml of 
interferon β in HeLa Kovak/ Kb cells transfected with no (grey shadow), Neo (orange) or 
Upf1 (red) RNAi in an acid wash recovery experiment. MHC class I levels are generally 
up regulated upon interferon β addition while slower MHC class I recovery in Upf1 
depleted cells persists. 
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2.3 Direct assessment of peptide supply using Fluorescence 
Recovery after Photo Bleaching (FRAP) 
 
 
So far T-cell assays as well as antibody measurements of pMHC class I on the cell 
surface helped to reveal the relationship between factors of the NMD associated pioneer 
round of translation and MHC class I mediated antigen presentation. While translation 
and the generation of polypeptides are the very first events within the antigen 
presentation pathway, the final presentation at the cell surface represents the very end of 
the process. Here an additional technique is introduced in order to monitor the peptide 
transport across the ER membrane as an intermediate and essential step for efficient 
antigen presentation. TAP1 and TAP2 form a heterodimer upon recognition of suitable 
peptide targets for transport (see introduction “From cytosol to ER: peptide transport via 
TAP) (Androlewicz, Anderson et al. 1993). Next the assembly of the peptide loading 
complex including the TAP heterodimer, MHC class I, ERp57, calnexin, calreticulin, 
tapasin and further factors drastically increases the molecular size of the multiprotein 
complex (Peaper and Cresswell 2008). Indeed the radius of the complete TAP-PLC 
complex has been estimated to be ~600-1.000 Å (Marguet, Spiliotis et al. 1999).  
Formation of the TAP-PLC complex decreases the lateral mobility of TAP1 within the 
ER membrane. Eric Reitz and Jaque Neefjes were the first to take advantage of this 
change in mobility as a direct measure for ongoing peptide transport (Reits, Vos et al. 
2000). Based on fluorescence recovery after photo bleaching (FRAP), a microscopy 
technique established already 30 years ago when fluorescent proteins became available, 
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this method enables to monitor peptide transport in single living cells (Fig.26). In 
subsequent experiments the peptide supply was either reduced by using inhibitors 
targeting translation proteasomal degradation or peptide binding to TAP or allowing for 
optimal peptide generation under conditions of ongoing translation and proteasome 
function in the presence of ATP. The ultimate goal of these experiments was to determine 
the involvement of the pioneer round of translation associated with NMD in the 
generation of peptides for TAP transport. 
 
 
Fig.26 Lateral mobility of TAP directly depends on peptide supply. The active 
transport and MHC class I binding of peptides leads to the formation of a TAP1 / TAP2 
heterodimer as well as the assembly of a multi protein peptide loading complex (PLC). 
The increase in molecular weight and size of the protein complex reduces its lateral 
mobility within the ER membrane. This information is used for a direct assay of peptide 
transport to the ER in human MelJuSo cells by tracking the movement of an eGFP-TAP1 
fusion protein with a fluorescence recovery after photo bleaching (FRAP) technique. 
Inhibitors of TAP, proteasome or translation increase TAP1-GFP mobility while 
conditions of active peptide generation decrease TAP1-GFP mobility. 
• TAP inhibitors 
• Proteasome inh. 
• Cycloheximide 
• Upf1/ CBP80 
• ATP 
• Proteasome 
• Protein synthesis 
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Human MelJuSo cells expressing a TAP1 protein with a C-terminal eGFP fusion were 
generously provided by the Neefjes laboratory. These cells have been described earlier as 
suitable targets for FRAP measurements (Reits, Vos et al. 2000). The correct assembly of 
the transfected TAP1-GFP with the endogenous TAP2 is essential for dimerization and 
peptide transport requiring an optimal ratio of about 1:1. Flow cytometric analysis of the 
TAP1-GFP expression revealed a multimodal pattern with subpopulations of low, 
medium and high TAP1-GFP expressing cells (Fig.27 top panel). Even after differential 
cell sorting of these subpopulations and sustained culturing of the cells the same 
multimodal pattern of TAP1-GFP expression was observed consistently. The MelJuSo 
cells were transiently transfected with siRNAi targeting either Upf1, neo or no RNA as 
described above. Initial TAP1-GFP as well as MHC class I expression was not effected 
by siRNA transfection. The cells were washed with citric acid for the removal of MHC 
class I surface complexes and placed under culture conditions for 2.5 or 5 hours prior to 
W6/32 antibody staining. Cells were analyzed for MHC class I surface expression as well 
as TAP1-GFP content. MelJuSo cells with depleted Upf1 protein demonstrated a delayed 
MHC class I surface recovery particularly after 2.5 hours. This effect was more 
pronounced for low than for high TAP1-GFP expressing cells. Only 29.5 % of low 
TAP1-GFP, but 45.4 % of medium and 57.4% of high TAP1-GFP expressing cells 
regained their full MHC class I surface level after 2.5 hours. This might be due to a  
generally higher protein biosynthesis in the subpopulation expressing high levels of 
TAP1-GFP. Therefore these cells might have a lower susceptibility for siRNA depletion. 
After 5 hours the majority of cells regained complete MHC class I surface expression 
independent of their TAP1-GFP expression of Upf1 depletion. Additionally cells were 
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permeabilized with Ethanol at -20°C and stained for intracellular Upf1 expression 
(Fig..27 bottom panel). This approach confirmed the down regulation of Upf1 protein 
expression upon siRNA transfection in low, medium and high TAP1-GFP expressing 
cells. In conclusion MelJuSo cells demonstrate Upf1 dependent MHC class I surface 
expression consistent with findings from experiments in HeLa cells. Cells with medium 
levels of TAP1-GFP expression were chosen for all following FRAP experiments since 
they combine both sufficient fluorescence for FRAP analysis as well as susceptibility for 
Upf1 dependent MHC expression. As recommended by Reits et al. they might also 
support a more efficient formation of the TAP heterodimer due to a more balanced ratio 
of TAP1-GFP to endogenous TAP2 proteins (Reits, Vos et al. 2000).  
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Fig.27 TAP1-GFP expressing MelJuSo cells demonstrate reduced MHC class I 
surface recovery after RNAi mediated Upf1 depletion. MelJuSo cells show a different 
intensity of TAP1-GFP expression (top panel). Cells with low, medium and high TAP1-
GFP expression were monitored for MHC class I surface expression in a acid wash 
recovery time course experiment before treatment and at 0, 2.5 and 5h. Cells 
demonstrated delayed MHC class expression after 2.5 h after Upf1 (red) depletion 
(middle panels, neo orange, no RNAi grey shadow).  Down regulation of Upf1 protein 
following RNAi transfection was demonstrated by detection of Upf1 protein levels in 
permeabilized cells with anti Upf1 antibody (bottom panel).  
 
 
 
MelJuSo TAP1-GFP cells show a typical staining of the ER and nuclear envelope 
(Fig.28). For FRAP measurements a region ω with a radius of 84 was monitored for 5 
time intervals of 1.6 seconds, fluorophores were bleached with a pulse at 100% laser 
intensity of a 488 nm Argon laser and monitored for fluorescence reassembly through 
lateral TAP1-GFP motion for another 32 seconds (ROI red). A general fading of about 3-
5 % of the initial fluorescence due to the detection laser was observed (ROI green). As 
depicted in the graph, an immobile fraction (I) as well an actively recovering mobile 
fraction (R) can be distinguished. Excluding microdomains, alterations of membrane 
shape and other obstacles the movement within the membrane can be described as planar 
Brownian motion. Different mathematical models have been used to generate a diffusion 
constant DFRAP. Here the equation for unrestricted two dimensional diffusion in a circular 
area without any recovery from outside the focal plane has been used (Axelrod, Koppel et 
al. 1976; Reits and Neefjes 2001; Chen, Lagerholm et al. 2006). This strategy has been 
successfully applied to determine diffusion constants for other membrane bound 
components including GFP-tagged MHC class I Ld molecules (Marguet, Spiliotis et al. 
1999). 
 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.28 Measuring Peptide transport with Fluorescence Recovery after Photo-
Bleaching (FRAP). TAP1-GFP was expressed in MelJuSO cells. A circular region was 
bleached at 100% laser intensity with an argon / krypton 488 nm laser and fluorescence 
recovery through lateral movement of TAP1-GFP was monitored at 1.6 second time 
intervals. A region on the opposing side of the cell was chosen as a reference for 
fluorescence due to fading. The lateral mobility of TAP1-GFP is calculated as DFRAP 
Diffusion coefficient. 
 
 
 
 
 
2.3.1 Inhibition of peptide supply increases TAP1-GFP membrane mobility 
 
Reits et al. postulated a direct correlation between cytosolic peptide supply and lateral 
TAP1-GFP mobility in the membrane (Reits, Vos et al. 2000). In order to establish an 
experimental set up to measure the transport of antigenic peptide, several of their 
experiments were recapitulated. First TAP1-GFP expressing MelJuSo cells grown on a 
R:  recovery rate, mobile fraction  
I:   immobile fraction,  
F:  fading of fluorescence 
R 1/2 R 
I 
ω:        radius of bleached region 
γ:         correction factor  
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DFRAP: diffusion coefficient for lateral motion 
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microscopy cover slip were incubated for 30 minutes at 37°C with medium containing 
200 µg/ml of the proteasome inhibitor lactacystin or medium alone. 10 cells of each 
condition expressing intermediate TAP1-GFP fluorescence were selected for FRAP 
analysis. The combined data for the cells with (green) or without lactacystin (black) are 
depicted in Fig. 29A. Incubation with the proteasomal inhibitor led to an accelerated 
fluorescence recovery indicating a higher lateral mobility of the TAP1-GFP molecule in 
the ER membrane. The TAP diffusion coefficient DTAP was determined as 6.63 x10-10 
(cm2 s-1) for lactacystin treated cells and as comparison to 3.98 x10-10 (cm2 s-1) for control 
cells. The effect of translational inhibition on TAP1-GFP mobility was tested using 
cycloheximide as an inhibitor of protein biosynthesis. Cells were incubated for 30 
minutes with cycloheximide at a concentration of 100 µg/ml (Fig.29B). A further 
approach included the direct interference with the TAP1/TAP2 heterodimer to interact 
with peptide for transport (Fig.29B). The Herpes simplex virus (HSV) derived immediate 
early protein ICP47 forms a stable complex between its N-terminal residues and the 
TAP1/TAP2 heterodimer therefore abolishing further peptide transport (Galocha, Hill et 
al. 1997). Cells treated with cycloheximide and control vector or jointly together with 
ICP47 encoding vector demonstrated a high DTAP of 8.47 x10-10 (cm2 s-1) and 8.75 x10-10 
(cm2 s-1) respectively, indicating the abrogation of peptide transport. In comparison 
ICP47 vector alone had a DTAP of 5.15 x10-10 (cm2 s-1) demonstrating a intermediate 
increase in TAP mobility in comparison to control transfected cells with a DTAP of 3.15 
x10-10 (cm2 s-1). Taken together inhibition of translation, proteasomal degradation and 
peptide transport all reduce lateral TAP mobility. This establishes TAP mobility as a 
good measure for peptide supply. 
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Fig.29 Inhibition of peptide supply increases TAP1-GFP membrane mobility. 
Protein degradation was inhibited by addition of 200 µg/ml proteasome inhibitor 
lactacystin (green) leading to accelerated fluorescence recovery with a DTAP of 6.63 in 
comparison to 3.98 x10-10 (cm2 s-1) for contral cells (A). Alternatively protein 
biosynthesis was inhibited with cycloheximide at a concentration of 100 µg/ml or TAP 
transport was reduced by vector transfection of the herpes simplex derived ICP47 (B). 
Both cycloheximide and ICP47 treated cells demonstrate a DTAP increase in comparison 
to control transfected cells indicating reduced peptide transport trough TAP. 
 
 
 
2.3.2 Upf1 depletion increases TAP1 mobility 
 
It was shown in previous experiments that siRNA induced depletion of Upf1 delays the 
recovery of surface MHC class I expression. Here we examined if Upf1 depletion also 
reduces the supply of peptides as measured by TAP1-GFP FRAP. MelJuSo cells were 
transfected with siRNA targeting Upf1 (red), neo (orange) or no RNA (black) (Fig.30A). 
As a control cells were incubated for 30 minutes with lactacystin (green).  Upf1 siRNA 
D TAP 
D TAP 
A 
B 
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transfected and lactacystin incubated cells both had a comparatively high DTAP of 8.26 
x10-10 (cm2 s-1) and 8.02 x10-10 (cm2 s-1). The DTAP of Neo siRNA or control cells 
remained similarly low at 4.75x10-10 (cm2 s-1) and 5.01x10-10 (cm2 s-1). The  difference in 
TAP mobility between Upf1 siRNA and untransfected cells is also reflected in Fig 30B. 
Treatment with lactacystin, cycloheximide or both chemical inhibitors together 
demonstrated an increasing DTAP value of  6.39x10-10 (cm2 s-1), 6.94x10-10 (cm2 s-1) and 
8.40x10-10 (cm2 s-1). This implies a potentially synergetic effect of the inhibitors in 
decreasing peptide supply. In conclusion Upf1 depletion reduces peptide supply available 
for TAP mediated transport to a comparable extend as chemical inhibitors of translation 
or proteasomal degradation. 
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Fig.30 hUpf1 depletion increases TAP mobility. MelJuSo cells were transfected with 
siRNA targeting hUpf1 (red), neo (orange) or no RNA (black). Additionally cells were 
treated with lactacystin (green) for proteasomal inhibition (A). TAP mobility was 
increased for both lactacystin and hUpf1 RNAi. In (B) cells were again transfected with 
hUpf1 (red) or no (black) siRNA or chemical inhibitors lactacystin (green), 
cycloheximide (brown) or both (dark green). Lactacystin and cycloheximide showed a 
cumulative effect of DTAP increase.  
 
 
 
2.3.3 Exogenous peptide supply partially reverses high TAP mobility 
 
 
The chemical inhibitors cycloheximidine and lactacystin as well as siRNA targeting Upf1 
increase TAP mobility. In order to verify that the higher TAP mobility is directly due to a 
lack of peptides for TAP association and transport, peptides of exogenous origin were 
supplied to the cells. Listeria monocytogenes infection was used as way to deliver 
peptides to the cytosol of the cells. The Listeria monocytogenes strain (acta-, LLO-kovak) 
expresses a LLO-kovak fusion protein in addition to its endogeneous genes. Further it 
should be noted that prokaryotic translation is not receptive to cycloheximide inhibition 
due to different ribosomal subunits. For the infection, cells were incubated for 1 hour 
with a MOI of 1:20. MelJuSo cells were transiently transfected with siRNA against Upf1 
prior to addition of Listeria monocytogenes (Fig.31A). Listeria infection reduced the 
TAP mobility of hUpf1 depleted cells from 6.06x10-10 (cm2 s-1) to 4.60x10-10 (cm2 s-1). 
Listeria monocytogenes induced a similar reduction in TAP mobility when added to 
cycloheximide treated cells bringing the DTAP from 6.49x10-10 (cm2 s-1) down to 4.62x10-
10 (cm2 s-1). 
Alternatively cycloheximide treated cells were incubated with a synthetic peptide in the 
culture medium at a concentration of 50 µM (light blue) leading to a decrease in TAP 
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mobility (Fig.32). TAP mobility demonstrates a modest drop from 6.35x10-10 (cm2 s-1) to 
5.45x10-10 (cm2 s-1) upon peptide addition.  Control cells had a DTAP of 3.77x10-10 (cm2 s-
1). Taken together this indicates that uptake of exogenous peptide from the culture 
medium or through infection from Listeria monocytogenes can reverse a high TAP 
mobility due to a drained peptide supply. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.31 Listeria monocytogenes peptide partially reverses high TAP mobility. 
MelJuSo cells were transiently transfected with hUpf1 (red) and infected with a kovak 
expressing Listeria monocytogenes (purple) strain for 1 hour at a MOI of 1:20. Infection 
and therefore exogenous peptide supply led to reduced TAP mobility. Similarly addition 
of Listeria monocytogenes (light blue) reduced the DTAP of cycloheximide (brown) 
treated cells (B).  
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Fig.32 Exogenous peptide supply partially reverses high TAP mobility. Synthetic 
peptide was added to the culture medium at a concentration of 50µM together with the 
translation inhibitor cycloheximide 1 hour prior to FRAP analysis.  TAP mobility 
demonstrates a modest drop from 6.35x10-10 (cm2 s-1) to 5.45x10-10 (cm2 s-1) upon peptide 
addition.  Control cells had a DTAP of 3.77x10-10 (cm2 s-1). 
 
 
In conclusion it was demonstrated that lateral mobility of the TAP1-GFP fusion protein 
in MelJuSO cells can be used to measure the active transport of peptide from the cytosol 
to the ER (Fig.34). The pool of peptides for TAP dependent transport depends on 
ongoing translation and proteasomal degradation as demonstrated with the chemical 
inhibitors cycloheamide and lactacystin. Depletion of hUpf1 and therefore inhibition of 
the pioneer round of translation reduces the amount of peptides available for TAP 
mediated transport and therefore increases DTAP. A higher TAP mobility is the direct 
result of a diminished pool of peptides for TAP interaction and transport as it can be 
reversed by additional supply of exogenous peptide sources.  
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DTAP 
no 
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Fig.33 Generation of peptides for TAP mediated transport. The generation of 
peptides for TAP transport from the cytosol to the ER requires ongoing translation and 
proteasomal degradation as inhibition with cycloheximide and lactacystin reduces TAP 
transport. Depletion of hUpf1 reduces TAP transport. Supply of exogenous peptide 
through Listeria monocytogenes or high concentrations of synthetic peptide can reverse 
this effect. The HSV derived protein ICP47 can bind to TAP inhibiting further transport.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHX 
 
 
Lac 
ICP47 
 104 
2.4 Antigen presentation in the hUpf1 transgenic mouse 
 
Previous chapters focused primarily on analyzing the relationship between antigen 
presentation and the pioneer round of translation of the NMD pathway in cultured cells. 
Approaches using RNA interference can be limited by transfection efficiencies, 
incomplete or only transient down regulation of target proteins or RNA mediated off 
target effects. Particularly when focusing on the immune system certain limitations of 
cell lines were apparent. Immunization studies in mice would represent the par excellence 
standard to provide evidence for pioneer peptides as source for antigen presentation and 
in vivo T-cell recognition. So far the attempt to generate a mouse line depleted for the 
Upf1 gene was not successful as loss of Upf1 expression was embryonic lethal at the 
blastocyst stage after only 3.5 days (Medghalchi, Frischmeyer et al. 2001). This finding 
not only speaks to the importance of NMD at the organismal level but also blocks the 
road to the generation of Upf1 knock out embryonic stem cells.  Dietz et al. tried to create 
a Cre-loxP  based Upf1 conditional knockout mouse.  Analysis of the resulting mice 
revealed only an incomplete depletion of the Upf1 gene (Dietz 2007).  
Therefore the potential of a transgenic Upf1 dominant negative mouse in altering NMD 
and the pioneer round of translation was evaluated. The human Upf1 dominant negative 
construct was described before in competing with the wildtype protein and reversing 
NMD facilitated mRNA downregulation (Sun, Perlick et al. 1998). Here the human Upf1 
R844C construct was used for the creating of a transgenic mouse by H. Dietz and 
colleagues and kindly provided to us. Verification of the successful integration of the 
hUpf1 R844C transgene was initially achieved by Southern blotting. Then a PCR based 
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method was established in order to amplify 213 base pair DNA fragment specific to the 
human protein (Fig34).  A set of TAP1 primers served as functional controls for the PCR 
reaction. A DNA sample from a previously by Southern blotting genotyped mouse as 
well as purified DNA of a hUpf1 expression vector were additional positive controls.  
Expression of the dominant negative hUpf1 protein was then established with 
immunoblotting using a mouse anti hUpf1 polyclonal antibody. The antibody does not 
cross react with the murine Upf1. A band at the proposed molecular weight of 137 kDa 
was detected in homogenized spleenocytes from a transgenic mouse but not from the 
wildtype mouse (Fig.35).  
 
 
 
 
 
 
 
 
 
Fig.34 Genotyping of hUpf1 dominant negative mice. DNA was purified from tail 
clips of mice. PCR primer specific for the human sequence of hUpf1 transgenic mice was 
used to identify mice that had the hUpf dominant negative sequence incorporated. PCR 
amplification of a 173bp TAP1 DNA fragment was use a positive control. Additional 
controls are no DNA, purified hUpf1 vector DNA, a previously with Southern blotting 
genotyped hUpf dominant negative mouse DNA and B6 wt mouse DNA. 
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Fig.35 Expression of the hUpf1 dominant negative protein. Spleenocytes were 
isolated, homogenized and separated on a 4-20 % SDS PAGE gradient gel with a 1:4 
dilution. Immunoblotting with a mouse polyclonal antibody recognizing only the human 
protein was used to very expression of the 137 kDa dominant negative Upf1 protein. 
 
 
2.4.1 Analysis of spleenocytes from hUpf1 dominant negative transgenic mice 
 
Spleenocytes were isolated from hUpf1 dominant negative transgenic or wildtype mice 
(Fig.36). After blocking of the Fc-receptors, cells were stained for surface MHC class I 
expression using antibodies CTKb α Kb, AF6.88.5 α Kb, C28.14.8 α Db and KH95 α Db. 
Additionally cells were characterized for the surface markers B220 for B-lymphocytes, 
CD8, CD4 and MHC class II. After testing of several mice no apparent differences were 
noted in the expression of any of these surface markers in hUpf1 dominant negative 
transgenic or wildtype mice. 
 
 
 
 
 
 
mouse spleen 
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Fig.36 Analysis of spleenocytes derived from hUpf1 dominant negative transgenic 
mice. Spleenocytes from each a transgenic hUpf1 d.n., a litter mate and a B6/C57 wt. 4 
month female mouse were extracted, Fc-receptor blocked and stained for MHC class I Kb 
and Db expression (top row) and B220, CD8, CD4 and MHC class II (bottom row). 
Surface expression of these markers did not reveal significant differences.  
 
 
 
2.4.2 MHC class I surface recovery of hUpf1 dominant negative bone marrow 
derived dendritic cells 
 
The steady state cell surface expression of MHC class I molecules often does not 
appropriately reflect the actual generation of MHC class I molecules and their peptide 
ligands within the cell. MHC class I complexes can be stable over longer times in 
association with their bound peptide. As for CBP80 or Upf1 RNAi depleted HeLa cells, 
the differences in peptide generation only became obvious when monitoring the assembly 
and presentation of new MHC class I peptide complexes using the acid wash and 
recovery approach described in chapter 2.2. Similarly the large differences in the peptide 
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repertoire of ERAAP deficient cells in comparison to wildtype antigen presenting cells 
did not became obvious by steady state detection of MHC class I surface expression but 
was discovered by rather detailed analysis of specific antigenic peptides by immunization 
studies (Hammer, Gonzalez et al. 2006). 
Therefore bone marrow derived dendritic cells were generated for acid wash MHC class I 
surface recovery experiments (Fig.37). The total cells from transgenic and wildtype mice 
were extracted from the murine femur and cultured for 5 days in the presence of GM-
CSF. Non-adhesive cells were treated with citric acid for 1 minute and placed under cell 
culture conditions for MHC class I recovery.  For flow cytometry analysis Fc-receptors 
were blocked and MHC class I were stained with antibody 28.14.8 anti DbLd and AF 6-
88.5 anti Kb or with a IgG2a isotope control. For both antibodies hUpf1 dominant 
negative transgenic spleenocytes showed a slightly higher expression than the wildtype 
cells. This remained true throughout the experiments at 0 hours directly after the acid 
treatment as well as after 5 hours of recovery. The recovery was incomplete after 5 hours 
as the cells take a longer time recovery to the original level. While primary cells derived 
from bone marrow represent a more heterogeneous cell population than cancer cell lines 
in tissue culture, the hUpf1 transgenic cells showed in multiple experiments a tendency to 
recover their MHC class I molecules faster than their wildtype counterparts. While this 
finding was unexpected at the beginning it might reflect a difference in the experimental 
approach between RNAi mediated depletion as described in previous chapters and 
dominant negative protein overexpression of Upf1. This will be further discussed below 
in section 3.4. 
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Fig.37 MHC class I surface recovery of hUpf1 dominant negative bone marrow 
derived dendritic cells. Bone marrow cells were extracted from femur bones of a 
transgenic hUpf1 dominant negative mouse (red) or a wildtype littermate (black). After 5 
days of GM-CSF culture non-adhesive cells were harvested, red blood cells lysed and 
surface MHC class I molecules removed using the acetic acid wash procedure. Fc-
receptors were blocked with CD 16-32 and cells were stained for Db and Ld (A) or Kb or 
with a IgG2a isotope control (grey shadow). hUpf1 dominant negative transgenic cells 
show slightly higher MHC class I levels in comparison to wt cells. 
 
 
2.4.3 Analysis of T-cell activation of hUpf1 dominant negative cells 
 
Flow cytometry based staining of MHC class I molecules gives a general picture of 
different MHC class I subgroups. T-cell activation represents a far more specific and 
sensitive assay but also takes the actual potential of MHC class I peptide complexes in 
triggering a T-cell mediated immune response into account. In the next approach six mice 
were analyzed for MHC class I antigen biding (Fig.37) and also for T-cell activation 
assays (Fig.38). The acid wash recovery time course was described above. Then 1x106 
murine antigen presenting dendritic cells from each time point were titrated in a 1:3 
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dilution series and incubated overnight with 105 T-cells in the presence of 5 µg/ml 
brefeldin A. Afterwards a CPRG assay was performed. 30NXZ T-cells recognize the Db 
restricted peptide SSVVGVWYL (SVL9) derived from the H13a histocompatibility gene 
(Hammer, Gonzalez et al. 2006). The 30NXZ T-cell responses are initially high before 
acid treatment at an absorbance between 1.0 and 1.1. Citric acid is efficient in removing 
SVL9 peptide from the cell surface as the 30NXZ T-cell response goes down to 0.3 at 0 
hours. After 5 hours an increased 30NXZ T-cell response was detected. This was 
particularly evident for the male hUpf1 dominant negative transgenic mouse shown by 
the red line. The 27.5Z T-cells recognize a Kb restricted peptide of unknown sequence. In 
comparison to 30NXZ T-cells their activation of  a T-cell response remains very low after 
5 hours with only a very small increase between 0 hours and 5 hours. The response does 
not allow for a clear distinction of intensities of transgenic or wildtype cells. Finally 
11p9Z T-cells are activated through the Db restricted antigen WMHHNMDLI (WI9) 
derived from the Y-chromosome encoded Uty gene (Greenfield, Scott et al. 1996). 
Accordingly only cells from male mice present this Db restricted peptide. Wells with a 
high density of 1x106 cells show an nonspecific response. Within the male mice there are 
no significant differences in the recovery. Taken together there are no obvious indicators 
for an altered MHC class I recovery pattern as detected by the T-cell lines 30NXZ, 27.5 
and 11p9Z. This reflects also additional experiments performed in repeat of this analysis. 
No clear effect of the hUpf1 dominant negative protein expression on T-cell activation 
reflects possibly mainly on this transgenic mouse being an insufficient experimental 
system as it will be reflected in further detail in the discussion. 
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Fig.38 T-cell activation of transgenic hUpf1 dominant negative mouse bone marrow 
derived dendritic cells. Bone marrow derived dendritic cells were cultured as described 
in Fig.37. 1x106 cells were diluted 1:3 in 96-well plates and incubated with 1x105 cells of 
three different hybridoma T-cell lines: 30NXZ Db SVL9 H13a, 27.5Z Kb and 11p9Z Db 
WI9 Uty. T-cell activity of antigen presenting cells  was assessed by CPRG assay. 
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3  Discussion 
 
Previous chapters examined several aspects of the relationship between the pioneer round 
of translation and MHC class I mediated antigen presentation. Experimental findings 
were presented for intron positioning (2.1), pioneer vs. cap-dependent translation (2.2), 
TAP mobility as a measure for peptide supply (2.3) and a transgenic mouse model. Here 
the technical approach, the validity of each of the experimental results and the 
implications for the MHC class I presentation pathway are discussed. Further these 
findings are put into a context for a general model of pioneer round of translation 
peptides as source for antigen presentation. Finally an outlook defines yet to be answered 
questions that open future perspectives.   
 
 
3.1 Pioneer peptides itself rather than the NMD mechanism are important for 
antigen presentation 
 
The first set of experiments (2.1) aimed to clarify if NMD alters the translation and 
presentation of antigenic peptides. A first hypothesis focused on mRNAs encoding an 
antigenic peptide as potential target for NMD. Two sets of three DNA constructs were 
created based on either the Invariant chain / and SIINFEHL or the ovalbumine derived 
kovak sequence including SIINFEHL. An intron was shuffled to the 3’ or 5’ position or 
completely deleted.  
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The intron at the 5’ UTR was mainly introduced in order to create a counterpart of the 3’ 
construct with the exact same size of the vector to avoid potential changes in transfection 
efficiency. At the same time alterations in the 5’ UTR might introduce a multitude of 
alternative initiation codons, sequences functioning as IRES, or with other cryptic or 
translation modifying elements that are difficult to account for (Komarova, Brocard et al. 
2006; Graber and Holcik 2007). Therefore the central focus of these experiments lies on 
the comparison between the 3’ and no intron constructs. This parallels the approach of 
many studies that helped to discover and examine the NMD pathway.  
 
A sharp contrast of the mRNA levels between the 3’ and no intron constructs was 
observed while there were only minor differences in antigen presentation. Since both 3’ 
and no intron constructs elicit a strong B3Z T-cell response in a direct presentation assay 
as shown in Fig.3, two additional approaches were chosen. DNA titration of the vectors 
(Fig.4) as well as extraction of the peptides and presentation by K89 cells (Fig.5) helped 
to quantify the B3Z T-cell response. While the no intron construct accounts for a slightly 
stronger T-cell activation than the 3’intron construct, this does not reflect the magnitude 
of difference in the mRNA levels as determined by RT-PCR. Since this pattern was 
detected for both the invariant chain / SIINFEHL and the kovak vector set these findings 
seem to outline a more general rule.   
 
At the same time two similar NMD-reporter vectors were published that included the 
advantage of eGFP expression for straightforward analysis of protein levels and decay 
(Paillusson, Hirschi et al. 2005). They were modified for the purpose of antigen 
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presentation assays by introducing the antigenic SIINFEHL sequence to the C-terminus 
of the protein. As already described by the authors in their publication the vectors 
achieved only modest transfection efficiencies and GFP expression levels. Nevertheless 
the system confirmed the 3’ intron construct to be a target of NMD by showing lower 
GFP expression than the no intron construct (Fig.7). Despite the different GFP levels the 
B3Z T-cell activation of both constructs remained almost identical. This strengthened the 
prior results based on the invariant chain / SIINFEHL and kovak constructs. The mRNA 
and protein level and therefore NMD activity does not directly account for the antigen 
presentation intensity.  
 
A recent study presented improved NMD-reporter constructs using a luciferase based 
system (Boelz, Neu-Yilik et al. 2006). This more robust NMD detection assay  jointly 
with the described SIINFEHL insertion for B3Z recognition is currently under 
investigation. 
 
A crucial finding for the direction of this study was the discovery of reduced antigenicity 
upon Upf1 and CBP80 depletion. HeLa Kb cells depleted for these essential factors of the 
NMD pathway and the pioneer round of translation reduced the response of B3Z T-cells 
independent of the intron position. For a mere NMD effect the 3’intron would be 
expected to increase in expression and peptide presentation. A plethora of this kind of 
examples can be found in the literature (Zhang, Sun et al. 1998; Sun and Maquat 2000). 
But in this case quite the opposite was observed. The lack of Upf1 and even more so 
CBP80 reduced the generation and presentation of peptides for antigen presentation.  
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In conclusion these findings not only demonstrate that there is no straight forward 
relationship between the extent of protein expression and antigen presentation, but point 
out the potential role of the pioneer round of translation itself in generating antigens for 
MHC class I mediated presentation. 
 
 
3.2 Time course experiments reveal the role of the pioneer round of translation for 
antigen presentation 
 
The results of the previous intron shuffling experiments altered the focus of this study. 
They indicated a direct role of the pioneer round of translation rather then the decay 
mechanism of NMD in antigen presentation. In section 2.2 first an experimental approach 
to distinguish between pioneer and bulk translation was developed. CBP80 and Upf1 
were identified as key components that built a stable complex exclusive for the pioneer 
round of translation (Hosoda, Kim et al. 2005). Transient siRNA mediated depletion was 
chosen as a method that depleted the target protein levels to ~20% as shown by 
immunoblotting while it did not effect viability of the cells during the course of the 
experiments (Fig.11). S35 methionin and cysteine incorporation assays demonstrated no 
reduction of protein biosynthesis in Upf1 or CBP80 depleted cells. Quite the opposite 
Upf1 inhibition rather increased the overall translation of about 15 %. As mentioned this 
finding is consistent with prior reports of Upf1 being involved in the upregulation of at 
least 197 genes by the factor of 1.9 or more (Mendell, Sharifi et al. 2004; Chan, Huang et 
al. 2007). Apart from that it should be noted that Upf1 might be involved in other 
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nonsense associated mechanisms. Target mRNAs of these pathways might be 
upregulated upon Upf1 reduction accounting for the 15% increase in translation. 
Generally the use of S35 incorporation includes the advantage over alternative antibody 
based techniques, that it enables the detection of any kind of polypeptide independent of 
functionality, conformation or truncation with very high sensitivity. In addition, this 
experiment served the purpose to verify the complete inhibition of translation through 
cycloheximide treatment at a concentration of 100 µg/ml for 1 hour at 37°C. These 
conditions were used in several subsequent experiments.  
Inhibition of cap dependent bulk translation by 4E-BP1 vector DNA and elF4E siRNA 
transfection represented two independent approaches. Despite the far larger molecular 
weight and potentially lower transfection efficiency of the ~5600 base pair 4E-BP1 DNA 
construct, it demonstrated a stronger inhibition of translation than the 21 base pair elF4E 
siRNA molecule. These data are in good correlation with previously published studies by 
other groups (Gingras, Gygi et al. 1999).  
In conclusion these results confirmed the validity of the experimental design to separately 
interfere with pioneer or bulk translation and to jointly inhibit overall translation with 
cycloheximide.  
 
The role of pioneer vs. bulk translation in antigen presentation was then put to the test in 
flow cytometry experiments using antibody staining against different MHC class I 
molecules. Monitoring the recovery of MHC class I molecules rather than the steady state 
surface expression was chosen as an experimental approach due to three earlier 
observations. First the MHC class I steady state expression of ERAAP deficient mice 
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revealed only minor changes on the surface while more elaborate assays elucidated 
significant differences in the antigen repertoire (Hammer, Gonzalez et al. 2006). 
Secondly the importance of new synthesis of peptides has already been described in the 
context of DRiPs as crucial for antigen presentation (Qian, Reits et al. 2006). And third 
the transient siRNA depletion might only effect newly generated peptides that were not 
assembled prior to the transfection. 
 
While immunoblotting confirmed the down regulation of Upf1, PABP2, CBP80 and 
CBP20 in a pooled cell homogenate, flow cytometry based detection in permeabilized 
cells helped to confirm the depletion on a per cell basis (Fig.14D). Acid wash recovery 
experiments revealed a significant delay of MHC class I surface recovery in Upf1, 
PABP2 and CBP80 depleted cells (Fig.14, Fig.15, Fig.16). Initially HeLa cells stably 
expressing kovak and Kb were used in these acid wash recovery studies since they allow 
for the detection of human MHC class I HLA A, B, C as well as murine Kb molecules 
(Fig.14). It was later noticed that expression of the murine Kb molecule in human HeLa 
cells competes and consistently reduces the surface level of human MHC class I 
expression (data not shown).  A subclone of HeLa cells lacking the additional Kb 
molecule (termed AS1) revealed an even larger delay in the recovery pattern of Upf1 and 
CBP80 deficient and control transfected cells (Fig.16).  
 
Antibody staining in conjunction with flow cytometry offers the opportunity to monitor 
overall changes in MHC class I molecules. T-cell activation assays enable to track the 
MHC class I mediated presentation of defined peptide sequences with exceptionally high 
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sensitivity. Three different T-cell lines B3Z, 18.5Z and 27.5Z were used that recognize 
either the stably transfected kovak derived SIINFEHL or two unknown human 
endogenous peptide sequences. Depletion of CBP80 reduced the T-cell response of 
recovering APCs in all cases (Fig.18). Also siRNA mediated inhibition of CBP20 
reduced the T-cell response to an intermediate level. CBP80 and CBP20 are equally 
important for the pioneer round of translation since they form a heterodimer that 
recognizes the newly spliced mRNA and facilitates the pioneer translation. Differences in 
the intensity of the T-cell response between CBP80 and CBP20 might be simply due to 
variations in the effectiveness of the siRNA in down regulating its target protein. The 
case might be different for Upf1 inhibition as it demonstrated a reduction in the T-cell 
response of 18.5Z and 27.5Z T-cells but no distinguishable effect on the B3Z response 
(Fig.17 and Fig.18). While no final explanations can be offered for this finding, at least 
two aspects should be pointed out. First the stably transfected kovak sequence might be 
integrated into the genome of the HeLa cells at different positions, which might alter 
gene regulation while the 18.5Z and 27.5Z recognized peptides are part of endogenously 
encoded proteins. Secondly, in contrast to CBP 80 and CBP 20, additional functions of 
Upf1 have been described by now that might alter the expression of different genes (Neu-
Yilik and Kulozik 2008). Furthermore peptide extraction from siRNA depleted cells and 
presentation by untreated APCs as described in Fig.17 represents the advantage of 
directly quantifying antigenic peptide. It helps to rule out potential effects of siRNA 
transfection or unspecific targeting of factors involved in MHC class I synthesis or 
regulation. Additional evidence for the involvement of the pioneer round of translation in 
antigen presentation comes from inhibition of hUpf2 through HeLa cells stably 
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expressing a small hairpin RNA (Fig.19). Two separate clones demonstrate a consistent 
five fold down regulation of MHC class I surface expression.   
 
So far several lines of evidence have been presented to demonstrate the requirement of 
ongoing pioneer translation for MHC class I mediated antigen presentation. The 
following experiments aimed to distinguish the effects of pioneer translation from cap 
dependent bulk translation as well as to further characterize how early events in 
translation control the final outcome of antigen presentation on the surface. 
 
An essential discovery was made with the identification of newly translated polypeptides 
as major source for antigen presentation. While the original finding of DRiPs has been 
strengthened substantially within the last decade through several studies, an exhaustive 
answer to why new translation products govern antigen presentation has not been offered 
yet. The experiment in Fig.20 recapitulated the importance of immediate early translation 
for antigenic peptide generation. A short time interval of 8 minutes of translation is 
sufficient to synthesize peptides that can be detected with the antibody W6/32 on the cell 
surface. Inhibition of translation with cycloheximide completely abrogates antigen 
presentation despite the presence of large pools of previously generated proteins present 
in the cell. The pretreatment of cells with cycloheximide 2 hours prior to the acid wash 
and short time intervals of translation of 0, 2, 8, 15, 30 and 60 minutes aimed to exclude 
peptides that were currently in the process of transfer from the ER through the Golgi 
network to the surface.  
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The experimental approach in Fig.21 further confirms the notion of new translation 
products being essential for MHC class I mediated antigen presentation. Addition of 
cycloheximide (black line) abrogates the surface recovery. The initial increase of detected 
MHC class I molecules between the 0 hour and 3 hour time point is likely to be due to 
peptides that were generated right before cycloheximide incubation and were already on 
their way though the ER trimming and Golgi transport to the surface. The inhibition of 
antigen surface recovery of cycloheximide treated cells is not simply due to a lack MHC 
class I synthesis as there is an abundant and stable pool of heavy chain present in the cell. 
A substantial amount of heavy chain could be detected even after 2, 24 and 48 hours of 
continuous translation inhibition (Fig.21C). The previously established system to 
exclusively target the cap dependent bulk translation provided particularly important 
information. Transfection with the 4E-BP1-AA dominant negative vector as well as 
targeting of elF4E directly with siRNA both did not interfere with MHC class I surface 
recovery (Fig.21 and Fig.22). While both 4E-BP1-AA dominant negative vector or elF4E 
siRNA transfection not completely abolish all bulk translation they did effect it 
substantially (Fig.12 and Fig.13). Therefore it remains remarkable that the reduction of 
bulk translation has no detectable effect on antigen presentation while inhibition of 
pioneer translation severely interferes with efficient MHC class I surface expression. 
 
The following experiments in Fig.23, Fig.24 and Fig.25 serve as important controls for 
the so far established results. Fig.23 revisited the bimodal recovery pattern of HeLa AS1 
cells after acid treatment. Co-transfection with fluorescence labeled siRNA demonstrated 
the equal transfection efficiency of both slower and faster recovering subpopulations of 
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cells. This helps to rule out a differential recovery due to different efficiency of siRNA 
mediated inhibition. Further, Fig.24 demonstrates that the extent of recovery correlates 
with PI staining for DNA with faster recovering cells showing also a faster progression 
through the cell cycle. Importantly hUpf1 siRNA did not directly effect the cell cycle 
progression within the course of the experiment as shown in the right panel of Fig.24. 
Findings have been confirmed with Hoechst 33342 staining in K89 cells. A recent report 
connected hUpf1 to the DNA damage response and repair (Azzalin and Lingner 2006). 
As the authors noted this is rather an effect of hUpf1 specific gene regulation than related 
to NMD or the pioneer round of translation in general. It has been stated before, that 
stable transfection with short hairpin RNA targeting Upf1 over a prolonged time period is 
lethal even in tissue culture cell lines (Wittmann, Hol et al. 2006).  
Lastly the effect of interferon β induction of MHC class I molecules during the acid wash 
recovery time course with hUpf1 depleted cells has been examined (Fig.25). This was 
mainly done to control for any potential effects of RNAi transfection in triggering an 
interferon response and potential alterations in MHC class I expression. Generally 
interferon β incubation up regulated the MHC class I surface expression at all stages of 
the experiment while leaving the relative difference between Upf1 depleted and control 
transfected cells unaltered. 
In conclusion chapter 2.2 established the direct importance of pioneer translation for 
MHC class I mediated antigen presentation. Furthermore it reaffirmed the requirement of 
immediate early translation for antigen synthesis and discounted the contribution of  
elF4E dependent bulk translation for the generation of antigenic peptides. 
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3.3 Antigen supply can be quantified during TAP transport  
 
The TAP1-GFP FRAP experiments were aiming to quantify the effect of pioneer peptides 
not only at the very end of the antigen presentation pathway at cell surface but at an 
intermediate step of the process. First previous findings of delayed MHC class I surface 
recovery upon hUpf1 depletion were successfully confirmed in MelJuSo cells (Fig.27). 
Due to the differential TAP1-GFP expression pattern this was also established for low, 
medium and high GFP expressing cells. As the FRAP assay is based on single cell 
measurements these aspects become more important. Statistical significance of the results 
was achieved by gathering and averaging the data for at least 10 cells for each graph as 
described in the literature (Reits, Vos et al. 2000; Reits and Neefjes 2001). Still this 
certainly showed a limitation of the statistical accuracy of this method in comparison to 
measurements using flow cytometry with results based on 20.000 ore more cells per 
sample. Special attention was given to the experimental setup, timing and temperature 
adjustments. After removal from the cell culture incubator cells were transported in a 
37°C water bath and analyzed with a microscope with a preheated sample frame in order 
to limit FRAP variations due to temperature inconsistencies. FRAP was originally 
established as a biophysical method quantifying the movement of freely diffusing or bi-
lipid membrane integrated molecules. Cellular measurements face additional challenges 
as the ER membrane is not a planar structure but heavily folded with inconsistencies 
including membrane rafts and intracellular movements. Taking all these effects into 
consideration the TAP1-GFP FRAP method established by Neefjes at al. represents an 
elegant method to measure peptide supply early on in the antigen presentation pathway. 
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Addition of small chemical inhibitors like lacacystin for the proteasomal degradation and 
cycloheximide for translation provide means to equally inhibit antigen presentation 
functions on cells attached to a microscope cover slip. Both show a significantly 
increased lateral TAP1-GFP mobility (Fig.29). This is in good correlation to their 
expected and previously published effect in decreasing the pool of peptides for TAP 
transport (Reits, Vos et al. 2000; Qian, Reits et al. 2006). Transfection with an ICP47 
encoding vector serves as a further control, as the ICP47 protein directly interacts with 
TAP1 therefore reducing its peptide transport and complex assembly. Next hUpf1 siRNA 
transfection was used to establish a connection between pioneer peptide translation and 
TAP1-GFP mobility (Fig.30). As demonstrated before siRNA transfection has a high 
transfection efficiency reducing the target protein expression in the whole transfected cell 
population. This is important since the number of cells for FRAP measurements is limited 
to about 10 cells per condition due to technical considerations. hUpf1 depleted cells 
showed a consistently increased TAP1-GFP mobility indicating a reduced peptide supply 
for TAP transport. Furthermore positive controls reversing the effect of peptide pool 
reduction by adding exogenous peptides were conducted.  
 
The addition of peptides through pathogen infection faces several challenges. First 
Listeria monocytogens are only infecting a subset of the given cells under the time course 
and conditions of the experiment (Fig.31). Since it would be an important improvement 
to the experimental approach to unequivocally distinguish highly infected from 
potentially uninfected cells for DTAP measurements, a GFP as well as a RFP expressing  
Listeria strains have been recently obtained and will be used for future experiments. They 
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will provide the additional opportunity to interfere with prokaryotic translation using 
specific inhibitors like tetracycline or eukaryotic translation using cycloheximide.  
 
The addition of synthetic peptide has been useful as another method of supplying peptide 
to the cell.  This method requires high concentrations of external peptide as TAP 
substrate to achieve significant cellular uptake. As shown in Fig.32 it has the potential to 
moderately decrease TAP1-GFP mobility. Streptolysin O, a bacterial membrane pore 
forming toxin, has been used to increase the uptake of exogenous peptides, but this 
approach faces the additional challenge of adding an additional compound that 
potentially alters membrane features for FRAP measurements. 
 
Finally microinjection represents an additional possibility to directly supply large 
quantities of peptide inside the cytosol of single cells cell. While this technique has 
already been used to reverse a high DTAP in MelJuSo cells, it would require to change 
form the current setup of an upright microscope to an inverted microscope to enable the 
use of micromanipulators for injection.  
 
Beside these future perspectives for the elaboration of the technique, the current results 
already provide a direct link between Upf1 mediated pioneer translation and the peptide 
supply for TAP transport. These findings further underline the importance of the pioneer 
round of translation for peptide generation. 
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3.4 Developing a mouse model for the pioneer round of translation  
  
At this stage only very limited mouse models for the NMD pathway are available.  
Since a complete depletion of Upf1 was embryonic lethal and a conditional knock out 
strategy did not lead to a complete excision of all functional exons of Upf1, an alternative 
approach was pursued (Medghalchi, Frischmeyer et al. 2001). A transgenic mouse based 
on the R844C dominant negative human Upf1 construct was created by H. Dietz and 
colleagues. In contrast to stable transfection of hUpf1 shRNA into HeLa cells, which is 
lethal after about 10 days of tissue culture, overexpression of the R844C mutant hUpf1 
protein in HeLa and COS cells is tolerated (Sun, Perlick et al. 1998; Wittmann, Hol et al. 
2006). Expression of the R844C dominant negative hUpf1 vector in tissue culture cells 
increased the expression of otherwise decayed PTC containing mRNA about three fold. 
Taken together the dominant negative hUpf1 R844C transgenic mouse represented the 
best available model for the examination of NMD and pioneer round of translation 
associated effects on the immune system. 
Integration of the transgene into the mouse genome was confirmed by Southern blotting 
(Dietz 2007) and PCR (Fig.34). Expression was verified by immunoblotting with an 
antibody specific for the human protein sequence of the transgene. No distinctive 
phenotype of the transgenic mouse could be detected for the surface expression of MHC 
class I, MHC class II, CD4, CD8 or B220 (Fig.36). T-cell responses after acid wash and 
recovery did not reveal consistent differences in activation of 30NXZ, 27.5Z or 11p9Z T-
cells (Fig.38). In several cases increased expression of Db, Ld and Kb was detected 
throughout acid wash recovery time course experiments (Fig.37). So far the Dietz lab did 
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not report any additional phenotype that might assist to determine the functionality of the 
hUpf1 transgenic mouse model. That led us to revisit several of the original Upf1 
mutagenesis studies in yeast as well as the current understanding of the domain structure 
of the mammalian Upf1 proteins (Czaplinski, Weng et al. 1995; Weng, Czaplinski et al. 
1996; Sun, Perlick et al. 1998). By now there is abundant evidence that hUpf1 is a protein 
with multivalent functions including early nuclear interactions with CBP80 and hUpf2, 
mRNA binding and translation termination as well as facilitating the final decay of target 
mRNAs in the cytosol. This leaves room to speculate about the exact function of the 
hUpf1 R844C mutation in interfering with NMD.  While the R844C mutation has been 
shown to interfere with the mRNA decay mechanism, the mutated protein might still be 
able to support other functions including mRNA binding and pioneer round of 
translation.  Indeed the overexpression of mouse and human Upf1 might even enhance 
some functions in the transgenic mouse therefore accounting for the slight increase of 
MHC class I expression observed in acid wash recovery experiments (Fig.37). The 
complex phosphorylation cycle of hUpf1 has been described in several studies but its role 
in NMD and the pioneer round of translation still remains indefinite (Conti and Izaurralde 
2005; Isken, Kim et al. 2008). An approach introducing mutations deleting the 
phosphorylation sites of Upf1 might be of promise. Additional experiments focusing on 
the less versatile proteins CBP80 and CBP20 of the pioneer round of translation are 
already under investigation. In this context several mutations were proposed that might 
interfere with the CBP80 / CBP20 heterodimer interface therefore disabling pioneer 
translation (Cusack 2006). Additionally lenti-virus based transduction or  “nucleofection” 
(Amaxa Biosystems, Cologne Germany) of RNAi into mouse embryonic cells are 
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alternative approaches to advance the experiments from immortalized tissue culture cells 
to mouse primary cells. And finally the most promising opportunities to examine the role 
of the pioneer round of translation for antigen presentation at an organismal level opened 
up with the recent advent of the hUpf2 dominant negative mouse model (Weischenfeldt, 
Damgaard et al. 2008). 
 
 
3.5 Final conclusions  
 
 MHC class I mediated antigen presentation depends on very early  translation.   
 
 Specific inhibition of cap-dependent bulk translation does not significantly 
 alter MHC class I dependent antigen presentation. 
 
 Interference with the pioneer round of translation reduces the pool of peptides 
 transported by TAP and presented by MHC class I on the cell surface. 
 
 
Taken together these findings put products of the pioneer round of translation at an 
important position as peptides for MHC class I mediated antigen presentation. 
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4 Materials and Methods 
 
4.1 Small interfering RNA oligomer design and transfection 
 
Synthetic small interfering RNA molecules targeting mRNAs were designed using the 
publicly available bioinformatics algorithm from the Whitehead Institute (Tuschl 2004) 
and generated by Dharmacon (Dharmacon, Chicago IL). Generally siRNA sequences 
consisted of double stranded 19-23 base pair oligomers with 3’ dTdT extensions. When 
indicated the design of previously validated and published siRNA molecules was used for 
oligomer synthesis. In the case of eIF4E and elF2B siRNA oligomers with a proprietary 
sequence were purchased. 
 
For transient depletion of the target mRNA 1 to 2.5 x 105 cells were plated per well of a 
6-well plate and incubated under growth conditions over night. Then medium was 
exchanged to 800 µl of serum free medium. siRNA oligomers were incubated for 20 
minutes with 4 µl of oligofectamine reagent (Invitrogen, Carlsbad CA) in 200 µl of  
serum without medium and added to the cells. After 3 hours 500 µl of medium containing 
3x serum was added. Cells were assayed for targeted mRNA or protein depletion after 48 
or 72 hours. 
 
 
 
 
 129 
4.2 List of small hairpin RNA oligomers: 
 
   hUPF1  
Definition:   homo sapiens up frame shift 1 
Alternative Names: rent1 regulator of  nonsense transcripts 
Accession Number:  NM_002911 
siRNA:   5’ GAUGCAGUUCCGCUCCAUUdTdT 3’ 
    3’ dTdTCUACGUCAAGGCGAGGUAA 5’ 
   (Mendell, ap Rhys et al. 2002) 
 
   mUPF1  
Definition:   mus musculus  up frame shift 1 
Alternative Names: rent1 regulator of nonsense transcripts  
Accession Number:  AY597038 
siRNA:   5’  GUGCCAGCUGCCAAAGCGCdTdT 3’ 
     3’ dTdTCACGGTCGACGGTTTCGCG 5’ 
 
   CBP80 
Definition:   homo sapiens nuclear cap binding protein subunit 1, 80 kDa  
Alternative Names: NCBP1  
Accession Number:  NM_002486 
siRNA:   5’  GCUGAUCUUCCUAACUACAdTdT 3’ 
     3’ dTdTCGACTAGAAGGATTGATGT 5’  
 
 
   CBP20 
Definition:   homo sapiens nuclear cap binding protein subunit 2, 20 kDa  
Alternative Names: NCBP2 
Accession Number:  NM_007362 
siRNA:              5’   CAGGUGUUUGACAAUUGAAUUdTdT 3’   
      3’ dTdTGTCCACAAACTGTTAACTTAA 5’ 
 
   PABP2 
Definition:   homo sapiens poly A binding protein, nuclear 1  
Alternative Names: PABPN1  
Accession Number:  NM_004643 
siRNA:   5’   AGAGUCAGUGAGGACUUCCdTdT  3’ 
      3’ dTdTTCTCAGTCACTCCTGAAGG 5’ 
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Neo  
Definition:   neomycin phosphotransferase II  
Alternative Names:  
Accession Number:   
siRNA:    5’ AAUGAACUGCAGGACGAGGCAdTdT 3’ 
   3’dTdTUUACUUGACGUCCUGCUCCGU 5’ 
   (Kunisawa and Shastri 2003) 
 
 
   eIF4E  
Definition:   homo sapiens eukaryotic translation initiation factor 4E  
Alternative Names:  
Accession Number:  NM_001968 
siRNA:  proprietary (Cell Signaling Technology, Danvers MA) 
 
 
   elF2B 
Definition:   homo sapiens elongation factor 2B  
Alternative Names:  
Accession Number:   
siRNA:  proprietary (Cell Signaling Technology, Danvers MA) 
 
 
In addition to synthetic small hairpin RNA molecules, several vector based RNA 
constructs were used. These mRNA hairpins require further processing by dicer and 
drosher within the cell to trigger degradation of their mRNA targets. In these cases cell 
lines were transfected as described and maintained under growth conditions including 1-5 
µg/ml puromycin as selective reagent. 
 
 
4.3 Vector based DNA and small hairpin RNA constructs 
 
The GFP-based NMD reporter constructs have been described in detail for the analysis of 
NMD in eukaryotic cells (Paillusson, Hirschi et al. 2005). The SIINFEHL encoding 
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sequence directly followed by a stop codon was introduced into the GFP-based NMD 
reporter genes by integration of a DNA fragment at the BsrGI restriction site. The DNA 
fragment was generated by synthesizing both strands 5’-TTAACCTGTACAAAAGT 
ATAATCAACTTTGAAAAACTCTGATTGTACATTAACC-3’ and 5’-GGTTAAT 
GTACAATCAGAGTTTTTCAAAGTTGATTATACTTTTGTACAGGTTAA-3’, 
annealing in a temperature gradient and BsrGI digestion. 
The small hairpin RNA constructs targeting hUpf1, hUpf2 and hSMG6 in the vector 
pSuper vector were kindly provided by Juergen Wittmann and Hans-Martin-Jaeck 
(University or Nuremberg-Erlangen, Germany) (Wittmann, Hol et al. 2006). The 
wildtype 4E-BP1 expression construct as well as the dominant negative (HA)-AA-4E-
BP1 (Thr37/46Ala) protein in the pACTAG2 eukaryotic expression vector and backbone 
vector without insertion were provided by Nahum Sonenberg (McGill University, 
Vancouver, Canada) and Diane Fingar (University of Michigan, Ann Arbor MI).  
The invariant chain (Ii) fused to Ova247-265 containing the SIINFEHL sequence were 
integrated into the pcDNA1 vector (Invitrogen, Carlsbad CA) using the EcoRI and XbaI 
site. The 3’ intron removal was achieved using two DraI sites. For 5’intron reintegration 
PCR based cloning using the forward primer 5’-CCCCAAGCTTTTAGAGGATC 
TTTGTGAAGGAACCTTACT-3’ and the backward primer 5’-CCCCGGATCCGCATT 
CATTTTATGTTTCAGGTTCAGG-3’ and the cloning sites HindIII and BamHI was 
used. For the generation of three kovak based expression constructs with shuffled intron 
positions, the OVA138-386 sequence was transferred into the pcDNA1 backbone vectors 
with the 3’, 5’ or no intron using the restriction sites EcoRI and XbaI. 
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The dominant negative human Upf1 expression construct with the arginine to cysteine 
mutation at residue 844 in the vector pCI was kindly provided by Harry Dietz (Johns 
Hopkins University, MD). CBP80 and CBP20 expression vectors for the generation of 
dominant negative interface mutations were shared by Ian Mattaj and Steven Cusack and 
have been mentioned in the literature before (Mazza, Ohno et al. 2001).  A luciferase 
dependent chemiluminescence NMD reporter system has been described recently (Boelz, 
Neu-Yilik et al. 2006). The pCi-neo expression vectors for the renilla luciferase β-globin 
fusion protein with or without a PTC as well as a firefly luciferase control vector have 
been provided by Andreas Kulozik (EMBL / University of Heidelberg).  
 
 
4.4 Cell lines and cell culture reagents 
 
HeLa (human), 293 (human), 293T (human), HFF (human) and COS-7 (green monkey) 
are well characterized cell lines that were acquired from the American Tissue Culture 
Collection (ATCC, Manassas VA). HeLa cells stably transfected for Kb or both Kb and 
the ovalbumin derived KOVAK 138-386 precursor and K89 Kb-L-cells (mouse) were 
described before (Kunisawa and Shastri 2003). MelJuSo (human) cells stably expressing 
a GFP-TAP I fusion protein were a generous gift form Jaque Neefjes and colleagues 
(Reits, Vos et al. 2000). The HeLa cell lines E1105 and E 1106 stably expressing hUpf2 
shRNA and the HeLa cell line E1086 stably expressing empty pSuper vector were kindly 
provided by Juergen Wittmann and Hans-Martin Jaeck (Wittmann, Hol et al. 2006). They 
were maintained in RPMI complete medium containing 1 µg/ml puromycin as selection 
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reagent. β-galactosidase (lacZ)-inducible 27.5Z, 18.5Z, 30NXZ, 11p9Z and B3Z T-cell 
hybridomas have been described earlier (Serwold, Gonzalez et al. 2002). Cell lines were 
maintained under growth conditions of 5 % CO2 and humidified air at 37°C.  DMEM 
(Invitrogen, Carlsbad CA) complete medium was used for culturing 293, 293T and 
MelJuSo cells. All other cell lines were maintained in RPMI 1640 (Invitrogen, Carlsbad 
CA) complete medium containing additional 2 mM glutamine, 1 mM sodium pyruvate, 
50 µM beta-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin (all: 
Invitrogen, Carlsbad CA) and 10 % fetal bovine serum (Hyclone, Logan UT).  
 
 
4.5 Mice and primary cells 
 
Transgenic mice expressing the human Upf1 dominant negative R844C protein on the B6 
background were received from the Dietz laboratory (Johns Hopkins University, 
Baltimore MD). Wildtype C57BL/6 (B6) mice were obtained from the Jackson 
Laboratory Bar Harbor, ME). For genotyping, DNA was purified from tail tissue using 
either the DNAeasy Tissue Kit (Qiagen, Valencia CA) or by phenol-chloroform 
extraction. The human Upf2 dominant negative DNA sequence was amplified by PCR 
using the forward primer 5’-GTCACAGCCCTTCTCTCAGG-3’ and the backward 
primer 5’–CCTGGTA CGTGGAGTCCTGT-3’. PCR amplification of TAP1 with the 
forward primer 5’-ATTGAAGTTCCTGCGCCTCC-3’ and the backward primer  5’-
AGGCTCAGCG TGCCACTAAT was used as a positive control. Expression of the 
dominant negative human Upf1 R844C protein was verified by immunoblotting with an 
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antibody recognizing only the human protein. Bone marrow dendritic cell cultures were 
used for characterizing Upf2 dominant negative transgenic cells including the analysis of 
MHC class I surface expression in acid wash recovery experiments. Murine cells were 
collected from the femur, treated with RBC lysis buffer for 1 minute and cultured in 
uncoated cell culture plates. GMCSF was added in the concentration of 10 ng/ml at day 3 
and day 5 (Lutz, Kukutsch et al. 1999). Spleen cell cultures were generated accordingly. 
Non-adhesive cells were collected at day 5 to 7 for analysis. Cells were blocked with 
anti-Fc receptor antibody (2.4G2) prior to antibody staining for flow cytometry 
assessment. Additionally B lymphocyte depletion was achieved using sheep anti mouse 
IgG Dynabeads according to the manufacturers instruction (Invitrogen, Carlsbad CA). 
 
 
4.6 Transient transfection of cell lines 
 
For presentation assays, 1 to 2.5 x 105 cells were plated in a single well of a 6-well plate, 
transfected with 1 µg of plasmid DNA after 24 hours of initial culture and assayed for 
gene expression after 48-72 hours. 3 µl of Fugene 6 (Roche, Indianapolis IN) was used as 
transfection reagent for each 1 µg of vector DNA. For cotransfection of plasmid DNA 
and RNAi, Oligofectamine reagent (Invitrogen, Carlsbad CA) was used as described 
above. As controls DNA encoding the appropriate empty vector only or GFP were used.  
Alternatively purified vectors were transfected with 100 µg/ml of DEAE-dextran and 100 
µM chloroquin in RPMI supplemented with 10 % Nu-serum as described before 
(Schenborn and Goiffon 2000). 
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4.7 Acid wash MHC class I surface recovery assay  
 
Adhesive cells were grown in 6-well plates washed with PBS and incubated for 3 minutes 
with acid solution containing 0.13 M citric acid and 0.066 M monobasic sodium 
phosphate at pH 3.1. These conditions remove bound peptides and β2m while leading to 
internalization of empty MHC class on molecules. Then the acid solution was aspirated, 
cells washed twice with 10 ml of PBS and placed again under growth conditions for 
various time points of MHC class I surface recovery for up to 20 hours. Semi-adhesive or 
suspension cells were lifted, transferred to 50 ml conical tubes, incubated with 2 ml of 
acid solution for 1-3 minutes, washed twice with 50 ml of PBS and placed under growth 
conditions for recovery.  For complete inhibition of translation of new peptides, 
cycloheximide (Sigma, St. Louis MO) was added to a final concentration of 100 µg/ml 
prior to acid wash. After the acid treatment cycloheximide in the same concentration was 
added in the recovery medium. MHC class I surface expression was consecutively 
assessed by flow cytometry with a FacScan (Coulter, Hialeah FL) and FlowJo software 
(Treestar, Ashland OR) and T-cell assay. 
 
 
4.8 Fluorescence recovery after photo bleaching 
 
Transport of peptides through TAP requires dimerization of TAP1 and TAP2 and is 
subsided by formation of the peptide loading complex (PLC) for transfer of peptides to 
the MHC class I complex. The size of the TAP dimer together with the PLC alters the 
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mobility within the ER membrane. In order to visualize the lateral mobility, TAP1 was 
fused to GFP and expressed in human MelJuSo cells. A region ROI1 with a diameter of  
0.84 µm was bleached by 20 itineration of  488nm Argon / Krypton laser pulse at 100 % 
intensity. GFP intensity in a reference region ROI2 at the opposing side of the cell was 
monitored in order to assess background photobleaching. Fluorescence was determined in 
a 20 cycle time course at 1.6 sec intervals at 25 % laser intensity by time lapse 
photography. For all microscope imaging a Zeiss 510 Axioplan META MaiTai at the 
Cancer Research Laboratory Molecular Imaging Center, UC Berkeley was used. Detailed 
FRAP protocols and studies were published before (Qian, Reits et al. 2006)(Reits and 
Neefjes 2001)(Reits, Vos et al. 2000). 
 
 
4.9 Peptide extraction 
 
For peptide extraction cell pellets were resuspended in 500 µl of 10 % acetic acid in 
water at a pH of  ~2 and boiled for 10 minutes. After 15 minutes of centrifugation at 
10,000 rpm supernatant was collected and liquid evaporated through vacuum 
centrifugation. Remaining peptides were resuspended in 50 µl PBS with 25 ng/ml phenol 
red. After completed resuspension for 30 minutes on ice, pH was balanced to ~7 using 
0.1 m NaOH. Remaining cell debris was pelleted through short centrifugation and 
supernatant was titrated in a 96 well plate 1:2 or 1:3 in a volume of 50 µl. 1x105 antigen 
presenting cells K89 and 1x105 hybridoma T-cells are added to each well. 
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4.10 T-cell activation assays 
 
Upon recognition of the Kb restricted SIINFEHL antigen, B3Z hybridoma T-cells express 
IL-2 promotor controlled β-galactosidase (LacZ) (Karttunen and Shastri 1991). 
Enzymatic LacZ activity was measured by chromogenic chlorophenol red β-D-
galactopyranoside (CPRG, 0.15 mM) (Roche, Indianapolis IN) catalysis to chlorophenol 
red in Z buffer (9 mM MgCl2, 0.125 % NP-40 alternative in PBS). Reaction product 
accumulation was read as 595 nm absorbance with a 635 nm reference wavelength using 
a Biorad Microplate Reader (Biorad, Hercules CA). Activation of 18.5Z, 27.5Z, 30NXZ 
and 11p9Z hybridoma T-cells was determined accordingly. 
 
For MHC class I presentation assays 1x105 T-cells were added in 96 well plates to serial 
dilutions of antigen presenting cells and cocultured overnight. Cells were spun down for 
2 minutes at 2,000 rpm, culture medium was removed and 100 µl of CPRG was added 
into each well. Plates were read after different incubation times.  
 
 
4.11 Western blotting 
 
Cells were lysed for 30 min. at 4°C with homogenization buffer (80 µl 1 M Tris-HCl pH 
7.6, 40 µl NP40 alternative, 20 µl 200 mM PMSF, 4 ml of H2O) containing a cocktail of 
protease inhibitors (either 4 µl 1mg/ml leupeptin, 2 µl 25 µM pepstation or one mini-
tablet of inhibitors (Roche, Indianapolis) and spun down at 10,000 rpm, 4°C for 30 min. 
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The protein supernatant excluding the pelleted nuclei was combined with the same 
volume of sample buffer and loaded on a 10 % or 4-20 % gradient SDS polyacrylamide 
gel (Biorad, Hercules, CA). Separated, denatured proteins were transferred onto a 
nitrocellulose membrane and transferred using a Bio-Rad trans blot apparatus with 25 
mM Tris, 0.192 M glycine and 20 % methanol as transfer buffer.  After blocking with 1% 
dry skim milk in PBS, membranes were probed with various primary antibodies and 
secondary horseradish peroxidase conjugated antibodies in the listed dilutions. Protein 
bands were visualized using the ECL western blotting detection kit (Amersham, 
Buckinghamshire UK). 
 
 
4.12 Primary Antibodies 
 
antibody species application source 
W6/32 α HLA A,B,C mouse α human  
monoclonal 
FC   1:500 ascites 
W6/32 α HLA A,B,C 
FITC conjugated 
mouse α human  
monoclonal 
FC   1:500 Sigma, St.Louis MO 
F-5662 
5F1.2.14 α Kb mouse 
monoclonal 
FC   1:500 ascites 
5F1.2.14 α Kb mouse 
monoclonal 
FC   1:500 supernatant 
α β2m mouse α human 
monoclonal 
FC    1:50 – 1:100 US Biological, 
Swampscott, MA 
M3890-5 
AF6-88.5 α Kb  
FITC conjugated 
 FC    1:50 BD Bioscience, San Jose 
CA 
KH95 α Db 
FITC conjugated 
 FC     1:50 BD Bioscience, San Jose 
CA 
C28.14.8 α Db 
FITC conjugated 
 FC     1:50 BD Bioscience, San Jose 
CA 
CTKb α Kb 
PE conjugated 
 FC     1:50 BD Bioscience, San Jose 
CA 
Y3 α Kb Kk mouse FC    1:500 ascites 
HC-10 α MHC I heavy 
chain 
mouse α human WB  1:100 
FC   1:50 
supernatant 
Helge Plough, MIT, MA 
α hUpf1 / rent1 mouse α human  
polyclonal 
WB  1:1000 Abcam, Cambridge, MA 
Ab43408 
α hUpf1 / rent1 goat α human 
polyclonal 
WB  1:1,000 – 1:2,500 
FC   1:100 
Abcam, Cambridge, MA 
Ab10510 & Ab10534 
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α hUpf2 rabbit α human  
polyclonal 
WB  1:100 Hans-Martin Jaeck 
Universitate Nueremberg-
Erlangen, Germany 
α CBP80 rabbit α human 
polyclonal 
FC   1:50 Abcam, Cambridge, MA 
α CBP80 rabbit α human 
polyclonal 
WB 1:500 Elisa Izaurralde, EMBL 
Heidelberg, Germany 
α CBP20 rabbit α human 
polyclonal 
FC   1:50 Abgent, San Diego, CA 
AP1946b 
α eIF4E rabbit α human 
polyclonal 
WB  1:1,000 Cell Signaling, Boston, 
MA 
6310 
α eIF4B rabbit α human 
polyclonal 
WB 1:500 - 1:1,000 Cell Signaling, Boston, 
MA 
6310 
α PABP2 rabbit α human 
polyclonal 
WB 1:1,000 Elmar Wahle, Universitaet 
Halle, Germany 
α 4E-BP1 rabbit α human 
polyclonal 
WB  1:1,000 Cell Signaling, Boston, 
MA 
9452 
α actin goat α human WB  1:2,000 SC-1615 
α neomycin 
phosphotransferase II 
rabbit α human  
polyclonal 
WB 1:1,000 Upstate, Lake Placid, NY 
α neomycin 
phosphotransferase II 
rabbit α human  
polyclonal 
WB 1:1,000 5Prime-3Prime 
α In-1 rat α human WB 1:500 subernatant 
α HA-Tag rabbit α human 
polyclonal 
WB 1:4,000 Abcam, Cambridge, MA 
Ab9110 
ME1 α HLA B0702 mouse α human FC 1:50 Abcam, Cambridge, MA 
 
 
 
 
 
4.13 Secondary Antibodies 
 
antibody application source 
goat α mouse IgG  
FITC conjugated 
FC   1:250 Cappel, Solon, OH 
sheep α mouse 
HRP conjugated 
FC   1:10,000  -  1:100,000  
goat α mouse IgG 
PE conjugated 
FC   1:200  
rabbit α goat IgG 
HRP conjugated 
WB   1:10,000 – 1:100,000 Zymax, San Luis Obispo, 
CA 
donkey α rabbit 
HRP conjugated 
WB   1:10,000 – 1:50,000 Amersham, Piscataway, NJ  
rabbit α rat 
HRP conjugated 
FC    1:10,000 – 1:100,00 Stressgen,AnnArbor, MI 
SAB-200 
swine α goat 
PE conjugated 
FC     1:200 Invitrogen, Carlsbad, CA 
1366799 
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4.14 Definitions 
 
Pioneer Translation: First round of translation of a mRNA after splicing in association 
with the EJC, CBP80, CBP20, Upf1 and PABP2. Might be located in close association 
with the nucleus or nuclear pore. 
 
Bulk translation: Exclusively elF4E dependent translation of bulk quantities of 
polypeptides and proteins in the cell. Might be termed steady state translation or 
conventional translation by some authors. 
 
Overall translation: All translational pathways that lead to the generation of 
polypeptides through ribosomal activity including bulk translation, pioneer translation, 
IRES dependent translation, cryptic translation, DRiP and RDP generation etc. 
 
4.15 Abbreviations 
 
17-AAG HSP90 inhibitor 
17-DMAG HSP90 inhibitor 
4E-BP1 elangation factor 4E binding protein 1 
α  anti 
APC  antigen presenting cell 
CBP20  also NCBP2 cap binding protein 20 kDa 
CBP80  also NCBP1 cap binding protein 80 kDa 
CPRG  chlorophenol red β-D-galactopyranoside 
DMSO  dimethyl sulfoxide 
EJC  exon junction complex 
elF-2B  elongation factor 2B 
elF-4B  elongation factor 4B 
elF-4E  elongation factor 4E (only cap-dependent bulk translation) 
elF-4G  elongation factor 4G (both cap dependent bulk and pioneer translation) 
EMCV  encephalomyocarditis virus 
ERAAP ER resident amino peptidase associated with antigen presentation 
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FC  flow cytometry 
FGF-5  fibroblast growth factor 
FITC   fluorescein resorcinolphthalein 
FRAP  fluorescence recovery after photo bleaching 
GFP  green fluorescent protein 
GM-CSF granulocyte monocyte colony stimulating factor 
GRP94 glucose-regulated peptide ~ 94 kDa, ER resident chaperone, =gp96 
gp96  see GRP94  
gp100  melanocytic growth protein 100 
h  human, homo sapiens 
HC  heavy chain of major histocompatibility complex class I 
HLA A/B/C human MHC class human lymphocyte antigen A, B, C 
Hoechst33342 flourescent dye, excitation nm, emission nm 
HPLC  High Performance Liquid Chromatography 
HRP  horseradish peroxidase 
HSP70 / 90 heat shock protein ~ 70 / 90 kDa, cytosolic 
HSV  Herpes simplex virus 
IRES  internal ribosome entry site 
ICP-47  infected cell protein 47, herpes simplex virus encoded TAP inhibitor 
Ii  invariant chain associated to major histocompatibility complex class II 
INF  interferon 
Kd  dissociation constant 
KOVAK ovalbumine derived peptide sequence of amino acids 138-386 
lac  lactacystin, organic compound, naturally synthesized by bacteria   
  Streptomyces, potent proteasome inhibitor 
LacZ  β-galactosidase 
LB  Luria Bertini bacterial growth medium 
LLM  N-acetyl-L-leucinyl-L-leucinyl-methional, weak 20S proteasome inhibitor 
LLnL  N-acetyl-L-leucinyl-L-leucinal-L-norleucinal, 20S proteasome inhibitor 
LPS  lipopolysaccharide 
LTA  lipoteichoic acid 
m  mouse, mus musculus 
MG115 N-carbobenzoxyl-L-leucinyl-L-leucinyl-L-norvalinal, potent proteasome  
  inhibitor  
MG132 N-carbobenzoyl-L-leucinyl-L-leucinyl-L-leucinal, potent proteasome  
  inhibitor 
MHC I  major histocompatibility complex class I 
MOI  multiplicity of infection 
OVA  chicken ovalbumin 
PA28  proteasome activator 
PABP2 poly adenin binding protein 2, also PABPN1 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PDI  protein disulfide isomerase 
PE  R-phycoerythrin 
PLC  peptide loading complex 
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PMSF  phenylmethanesulphonylfluoride 
POMP  proteasomal maturation protein 
PTC  premature termination codon 
RBC  red blood cell lysis buffer 
rent1  regulator of upframe shift, also Upf1 
RF1.Aa rattus norwegicus TAP allel 
rmp  rounds per minute 
siRNA  small interfering RNA 
shRNA small hairpin RNA 
SDS  sodium dodecyl sulfat 
SHL8  ovalbumine amino acids 257-264 SIINFEHL, K to H substitution 
SL8  ovalbumine derived peptide sequence of amino acids 257-264 SIINFEKL 
SMG-1 to 7 suppressor with morphogenic effect on genitalia-1 to 7 
SRP  signal recognition pore 
TAP  transporter associated with antigen processing 
TLR  toll-like receptor 
TPP  tripeptidyl peptidase  
TRiC  TCP-1 containing ring complex, group II chaperonin 
UL49.5  bovine herpes virus type 1 encoded TAP inhibitor 
Upf1  upframe shift protein 1, also rent1 
Upf2  upframe shift protein 2 
US6  human cytomegalovirus encoded TAP inhibitor  
UTR  untranslated region of a gene in 3’ or 5’ position 
VDJ  gene rearrangement of immunoglobulin und TCR genes 
WB  western blotting 
X-P  petide with X= any amino acid and P=prolin 
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6.3 Zusammenfassung 
MHC I vermittelte Antigenpräsentation von Peptiden der “nonsense mediated 
decay” assoziierten Pionier-Runde der Translation.  
 
“Nonsense mediated decay” (NMD) spielt eine entscheidende Rolle in dem 
Qualitätskontroll-Mechanismus, der Zellen vor Stopp-Mutationen, so genannten 
“premature termination codons” (PTC) schützt. Erkennung dieser PTCs erfordert eine 
Pionier-Runde der Translation noch vor Beginn der konventionellen Translation von 
mRNA. Diese führt zur Synthese sehr früher Peptide. 
Die Effektivität der Immunüberwachung wird in entscheidendem Masse von der 
schnellen und vollständigen MHC I vermittelten Präsentation von exakt prozessierten 
Peptiden, die alle zellulären Proteine repräsentieren, gewährleistet. Bisher ist bekannt, 
dass diese Peptide konventionell prozessierte Proteine, defekte ribosomale Produkte 
(DRiPs), und kryptische Peptide, deren Translation nicht mit einem AUG-Codon beginnt, 
umfassen. Hier wurde untersucht, welchen Beitrag Peptide aus der Pionier-Runde der 
Translation zu der MHC I vermittelten Antigenpräsentation leisten. Reduktion der für die 
Pionier-Runde der Translation essentiellen Faktoren hUpf1 und CBP80 führt zu 
verminderter Antigenpräsentation. Im Gegensatz dazu führt eine Reduktion der  
konventionellen Translation ohne Einschränkung der Pionier-Translation zu keiner 
Veränderung der MHC I vermittelten Antigenpräsentation. Aus diesen Ergebnissen geht  
die entscheidende Bedeutung der Peptide der Pionier-Runde der Translation für die 
Antigenpräsentation hervor und stellt eine neue Verbindung zwischen NMD und dem 
Immunsystem dar. 
